var title_f8_7_8304="Doppler restrictive CM I";
var content_f8_7_8304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Doppler in restrictive cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pulse wave Doppler in a patient with an idiopathic restrictive cardiomyopathy demonstrates an increased E/A ratio (2.4), with shortened deceleration time (DT = 128 milliseconds).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Naser Ammash MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8304=[""].join("\n");
var outline_f8_7_8304=null;
var title_f8_7_8305="Squamous CA lung cytology";
var content_f8_7_8305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cytology specimen showing the typical appearance of squamous cell carcinoma of the lung. The malignant cell has an enlarged hyperchromatic nucleus and darkly staining cytoplasm with an irregular configuration including a cytoplasmic tail (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8305=[""].join("\n");
var outline_f8_7_8305=null;
var title_f8_7_8306="MRCP in a patient with primary sclerosing cholangitis";
var content_f8_7_8306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance cholangiopancreatography in a patient with primary sclerosing cholangitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 402px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A thick slab coronal magnetic resonance image of the liver in a patient with primary sclerosing cholangitis. The image sequence shows all bile ducts with a bright white signal. Note the beaded duct in the left lobe (large white arrow) as well as the many dilated intrahepatic ducts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8306=[""].join("\n");
var outline_f8_7_8306=null;
var title_f8_7_8307="Patient information: Ankylosing spondylitis (The Basics)";
var content_f8_7_8307=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/22/9571\">",
"         Patient information: Arthritis and exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/0/29698\">",
"         Patient information: Reactive arthritis (Reiter syndrome) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/38/19045\">",
"         Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/60/23491\">",
"         Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/40/27266\">",
"         Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/0/30721\">",
"         Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ankylosing spondylitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ankylosing-spondylitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H23672450\">",
"      <span class=\"h1\">",
"       What is ankylosing spondylitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ankylosing spondylitis is a disease that causes pain and stiffness in the back, neck, and hips. It begins with inflammation around the bones in the spine or in some joints. Later, it causes the bones in the spine to fuse together.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23672465\">",
"      <span class=\"h1\">",
"       What are the symptoms of ankylosing spondylitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptom is pain in the low back. This pain usually:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Starts between the ages of 20 and 30",
"       </li>",
"       <li>",
"        Comes on slowly",
"       </li>",
"       <li>",
"        Lasts for more than 3 months",
"       </li>",
"       <li>",
"        Is worse after resting, such as first thing in the morning",
"       </li>",
"       <li>",
"        Feels better with movement",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The back might also become less flexible. This can make it harder to do things like bend forward to put on socks or shoes.",
"     </p>",
"     <p>",
"      Other symptoms might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain or arthritis in other joints, such as the hips or shoulders",
"       </li>",
"       <li>",
"        Pain or swelling in other parts of the body, such as the elbows, heels, or ribs",
"       </li>",
"       <li>",
"        Feeling tired and not well",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In rare cases, ankylosing spondylitis can lead to other problems, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Inflammation of part of the eye &ndash; This is called &ldquo;iritis&rdquo; or &ldquo;uveitis,&rdquo; and causes eye pain and blurry vision.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Problems with the spinal cord &ndash; Ankylosing spondylitis makes it more likely that the spine will break in an accident. This can hurt the spinal cord.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Problems with the way the heart valves work",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Breathing problems &ndash; Some people have stiffness between the ribs and spine. This can make it harder to breathe deeply and to exercise.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Inflammation of the inside of the intestines, which usually does not cause any obvious symptoms",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23672480\">",
"      <span class=\"h1\">",
"       Is there a test for ankylosing spondylitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no one test that can tell if you have ankylosing spondylitis. But your doctor or nurse should be able to tell if you have it by learning about your symptoms, doing an exam, and using imaging tests to look at your bones and joints.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23672495\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can reduce the chance that your condition will cause problems if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stop smoking &ndash; If you smoke and have ankylosing spondylitis, you will be more likely to have breathing problems. Quitting smoking can help with this.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Exercise &ndash; Exercise can help prevent some of the stiffness caused by ankylosing spondylitis. Follow your doctor&rsquo;s instructions for exercising and stretching.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get plenty of calcium and vitamin D &ndash; This can help to keep your bones from getting weak.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Use a thin pillow &ndash; Sleeping on a thick pillow can cause neck problems in people with ankylosing spondylitis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23672510\">",
"      <span class=\"h1\">",
"       How is ankylosing spondylitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your symptoms and how severe your condition is. The goal of treatment is to relieve your symptoms, help you do your normal activities, and keep your condition from causing other problems.",
"     </p>",
"     <p>",
"      Exercise is an important part of treating ankylosing spondylitis. Some people work with a physical therapist (an exercise expert) to learn the best way to exercise. As part of their exercise routine, most people work on posture, do deep breathing, and stretch their back.",
"     </p>",
"     <p>",
"      Many people with ankylosing spondylitis also take one or more medicines. These might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        NSAIDs &ndash; This is a large group of medicines that includes",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;). These medicines can help relieve pain and stiffness.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Other medicines &ndash; There are other medicines that can help treat symptoms and keep ankylosing spondylitis from getting worse. Your doctor or nurse will decide which medicines are best for you.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Surgery can help some people with severe ankylosing spondylitis. For instance, some people have hip replacement surgery to replace a bad hip joint.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23672525\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ankylosing spondylitis can make it hard to do simple things, such as getting dressed, getting up from a sitting position, and looking side to side. You might need help from family or friends.",
"     </p>",
"     <p>",
"      Your condition puts you at risk of serious back injury. To reduce the chances that you will get hurt:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Remove loose rugs, electrical cords, and any clutter that could make you trip",
"       </li>",
"       <li>",
"        Do not drink a lot of alcohol or take sleeping pills",
"       </li>",
"       <li>",
"        Avoid sports or activities that might cause injury",
"       </li>",
"       <li>",
"        Always wear a seatbelt while riding in a car",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23672541\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/0/29698?source=see_link\">",
"       Patient information: Reactive arthritis (Reiter syndrome) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=see_link\">",
"       Patient information: Arthritis and exercise (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=see_link\">",
"       Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/0/30721?source=see_link\">",
"       Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"       Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/7/8307?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16164 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8307=[""].join("\n");
var outline_f8_7_8307=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23672450\">",
"      What is ankylosing spondylitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23672465\">",
"      What are the symptoms of ankylosing spondylitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23672480\">",
"      Is there a test for ankylosing spondylitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23672495\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23672510\">",
"      How is ankylosing spondylitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23672525\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23672541\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=related_link\">",
"      Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=related_link\">",
"      Patient information: Arthritis and exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/0/29698?source=related_link\">",
"      Patient information: Reactive arthritis (Reiter syndrome) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/0/30721?source=related_link\">",
"      Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_7_8308="Serosal repair after myomectomy";
var content_f8_7_8308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serosal repair after myomectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8308=[""].join("\n");
var outline_f8_7_8308=null;
var title_f8_7_8309="How to swaddle PI";
var content_f8_7_8309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    How to swaddle a baby",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 561px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swaddling a baby can help stop crying or fussing. To swaddle a baby:",
"    <br/>",
"    <ol>",
"     <li>",
"      Put your baby on a large blanket that has the top corner folded down (as shown in A).",
"     </li>",
"     <li>",
"      Bring the left side of the blanket tightly across the baby's shoulder and chest, and tuck it snugly under the right side of the body (as shown in B and C).",
"     </li>",
"     <li>",
"      Pull up the bottom of the blanket and tuck it snugly behind the baby's right shoulder (as shown in D).",
"     </li>",
"     <li>",
"      Pull the right side of the blanket tightly across the baby's chest and tuck it snugly under the left side of the body (as shown in E and F).",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8309=[""].join("\n");
var outline_f8_7_8309=null;
var title_f8_7_8310="Hookworm life cycle";
var content_f8_7_8310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Intestinal hookworm infection life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 492px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Eggs are passed in the stool",
"    <strong>",
"     (1)",
"    </strong>",
"    , and under favorable conditions (moisture, warmth, shade), larvae hatch in 1 to 2 days. The released rhabditiform larvae grow in the feces and/or the soil",
"    <strong>",
"     (2)",
"    </strong>",
"    , and after 5 to 10 days (and two molts) they become filariform (third-stage) larvae that are infective",
"    <strong>",
"     (3)",
"    </strong>",
"    . These infective larvae can survive 3 to 4 weeks in favorable environmental conditions. On contact with the human host, the larvae penetrate the skin and are carried through the blood vessels to the heart and then to the lungs. They penetrate into the pulmonary alveoli, ascend the bronchial tree to the pharynx, and are swallowed",
"    <strong>",
"     (4)",
"    </strong>",
"    . The larvae reach the small intestine, where they reside and mature into adults. Adult worms live in the lumen of the small intestine, where they attach to the intestinal wall with resultant blood loss by the host",
"    <strong>",
"     (5)",
"    </strong>",
"    . Most adult worms are eliminated in 1 to 2 years, but the longevity may reach several years. Some A. duodenale larvae, following penetration of the host skin, can become dormant (in the intestine or muscle). In addition, infection by A. duodenale may probably also occur by the oral and transmammary route. N. americanus, however, requires a transpulmonary migration phase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention.",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/hookworm.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/hookworm.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8310=[""].join("\n");
var outline_f8_7_8310=null;
var title_f8_7_8311="Clinical features and diagnosis of placenta accreta, increta, and percreta";
var content_f8_7_8311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of placenta accreta, increta, and percreta",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/7/8311/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8311/contributors\">",
"     Robert Resnik, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/7/8311/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8311/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8311/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/7/8311/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8311/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/7/8311/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta accreta refers to an abnormality of placental implantation in which the anchoring placental villi attach to myometrium rather than decidua, resulting in a morbidly adherent placenta. Placenta increta (chorionic villi penetrate into the myometrium) and placenta percreta (chorionic villi penetrate through the myometrium to the uterine serosa or adjacent organs) are related, but more severe, abnormalities of placental implantation. The pathogenesis is primarily attributed to defective decidualization of the implantation site [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unless otherwise noted, the following discussion of placenta accreta applies to all depths of placental invasion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta accreta is much more common than placenta increta and percreta. In a pooled analysis of results from two series involving a total of 138 histologically confirmed, abnormally implanted placentas from hysterectomy specimens, the type and frequency of abnormal placentation were [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Placenta accreta: 79 percent",
"     </li>",
"     <li>",
"      Placenta increta: 14 percent",
"     </li>",
"     <li>",
"      Placenta percreta: 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 1950, placenta accreta was rare, occurring in 1 in 30,000 deliveries in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. During the 1980s and 1990s, the incidence markedly increased, ranging from 1 in 533 to 1 in 2510 deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The marked increase has been attributed to the increasing prevalence of cesarean delivery in recent years (see",
"    <a class=\"local\" href=\"#H3937600\">",
"     'Risk factors'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3937332\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of placenta accreta is not known with certainty. The most common theory is that defective decidualization (thin, poorly formed, or absent decidua) related to previous surgery or to anatomical factors (endocervix, lower uterine segment, endosalpinx, uterine anomaly) allows the placenta to attach directly to the myometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. This theory is supported by the observation that 80 percent of these cases are associated with a history of previous cesarean delivery, curettage,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/1\">",
"     1",
"    </a>",
"    ]. Other theories, which may account for a proportion of cases, attribute placenta accreta to&nbsp;excessive extravillous trophoblastic invasion or defective maternal vascular remodeling in the area of a hysterotomy scar [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occurrence of placenta increta and percreta may be due to partial or complete dehiscence of a uterine scar, which allows the extravillous trophoblast direct access to the deeper myometrium, serosa, and beyond [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/1\">",
"     1",
"    </a>",
"    ]. There are confirmed cases of placenta percreta as early as 16 weeks of pregnancy, which suggests that, at least in some cases, the \"die is cast\" at implantation as to whether an accreta, increta, or percreta will develop and that increasing depth of invasion is not related to increasing duration of gestation. However, the factors that regulate the extent of pathological invasion (eg, accreta versus percreta) are undefined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41256?source=see_link\">",
"     \"Placental development and physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3937600\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important risk factor for placenta accreta is placenta previa after a prior cesarean delivery. In women with placenta previa, the frequency of placenta accreta increases with an increasing number of cesarean deliveries as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No previous cesarean birth, 1 to 5 percent",
"     </li>",
"     <li>",
"      One previous cesarean birth, 11 to 25 percent",
"     </li>",
"     <li>",
"      Two previous cesarean births, 35 to 47 percent",
"     </li>",
"     <li>",
"      Three previous cesarean births, 40 percent",
"     </li>",
"     <li>",
"      Four or more previous cesarean births, 50 to 67 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of placenta previa, the frequency of placenta accreta still increases with an increasing number of cesarean deliveries, but the incidence is much lower. In women without placenta previa, the frequency of placenta accreta is [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One previous cesarean birth, 0.3 percent",
"     </li>",
"     <li>",
"      Two previous cesarean births, 0.6 percent",
"     </li>",
"     <li>",
"      Three previous cesarean births, 2.4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interestingly, the sex ratio associated with placenta accreta favors females, which is opposite to the normal sex ratio in the general population, which favors males [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3939541\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, placenta accreta is first suspected because of findings on obstetrical ultrasound examination while the patient is asymptomatic. The abnormally implanted placenta is often diagnosed on prenatal sonographic evaluation of the placenta in a woman with risk factors for accreta (previa, previous cesarean delivery), but may be an incidental finding. (See",
"    <a class=\"local\" href=\"#H3939740\">",
"     'Ultrasonography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The first clinical manifestation of placenta accreta is usually profuse, life-threatening hemorrhage that occurs at the time of attempted manual placental separation. Part, or all, of the placenta remains strongly attached to the uterine cavity, and no plane of separation can be developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15006491\">",
"    <span class=\"h2\">",
"     Sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poorly controlled hemorrhage related to placenta",
"    <span class=\"nowrap\">",
"     accreta/increta/percreta",
"    </span>",
"    is the indication for one to two thirds of peripartum hysterectomies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Additional potential sequelae of massive hemorrhage include disseminated intravascular coagulopathy, adult respiratory distress syndrome, renal failure, unplanned surgery, and death.",
"   </p>",
"   <p>",
"    There is limited information on perinatal outcome in pregnancies complicated by placenta accreta. One case-control study including 310 patients with placenta accreta reported a significant increase in preterm birth (11 versus 1 percent in controls) and small for gestational age infants (27 versus 14 percent in controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/14\">",
"     14",
"    </a>",
"    ]. Neonatal outcome does not appear to be significantly affected by depth of placental invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review including 109 cases of placenta percreta reported the following types and frequencies of complications: transfusion of over 10 units (44 cases), infection (31 cases), perinatal death (10 cases), maternal death (8 cases), ureteral ligation or fistula formation (5 cases each), and spontaneous uterine rupture (3 cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/16\">",
"     16",
"    </a>",
"    ]. These cases were derived from a questionnaire issued to members of the Society for Maternal-Fetal Medicine and a retrospective study at one institution; therefore, the complication rates may be higher than those that would be observed from a prospective consecutive series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3939548\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3939740\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most useful modalities for evaluating placental position and implantation are transabdominal and transvaginal ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In studies with more than 30 subjects, the sensitivity and specificity of ultrasound for detection of placenta accreta were 77 to 90 percent and 71 to 98 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/18-22\">",
"     18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the second and third trimesters, sonographic findings suggestive of placenta accreta include the following (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63825 \" href=\"UTD.htm?41/8/42115\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/17,23\">",
"     17,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of placental homogeneity, which is replaced by intraplacental sonolucent spaces (venous lakes or placental lacunae) adjacent to the involved myometrium. This is the most consistent ultrasound finding.",
"     </li>",
"     <li>",
"      Loss or thinning of the normal hypoechoic area behind the placenta (termed the &lsquo;clear space&rsquo;).",
"     </li>",
"     <li>",
"      Loss or disruption of the normally continuous white line representing the bladder wall-uterine serosa interface (termed the &lsquo;bladder line&rsquo;)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A first trimester sonographic finding suggestive of placenta accreta is a gestational sac located in the lower uterine segment (rather than the fundus), next to or lower than the hysterotomy scar [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The characteristic second trimester placenta accreta findings of anechoic placental areas and an irregular placental-myometrial interface may also be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27505539\">",
"    <span class=\"h4\">",
"     Three-dimensional ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional (3D) ultrasound has also been used successfully for evaluation of placenta accreta [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Diagnostic criteria include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irregular intraplacental vascularization with tortuous confluent vessels crossing placental width",
"     </li>",
"     <li>",
"      Hypervascularity of uterine serosa&ndash;bladder wall interface",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of 187 patients with placenta previa and a history of uterine surgery, 97 of 146 patients without a confirmed morbidly adherent placenta had none of the 5 two-dimensional (2D) or 3D ultrasound findings associated with morbidly adherent placenta and the remaining 49 patients had only 1 finding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/28\">",
"     28",
"    </a>",
"    ]. By comparison, none of the 41 patients with a morbidly adherent placenta (placenta accreta or worse) had 0 or 1 of these findings; 5 had 2 findings and the remainder had 3 to 5 findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3939747\">",
"    <span class=\"h4\">",
"     Color Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific findings on color Doppler ultrasonography that suggest placenta accreta include (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83270 \" href=\"UTD.htm?19/54/20326\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/19,27,29\">",
"     19,27,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diffuse or focal intraparenchymal lacunar flow",
"     </li>",
"     <li>",
"      Vascular lakes with turbulent flow",
"     </li>",
"     <li>",
"      Hypervascularity of serosa-bladder interface",
"     </li>",
"     <li>",
"      Prominent subplacental venous complex",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 3D study discussed above also evaluated color Doppler ultrasound of 170 women with placenta previa, of whom 39 had previa-accreta confirmed at cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/27\">",
"     27",
"    </a>",
"    ]. The sensitivity and specificity of color Doppler for diagnosis of placenta accreta was 92 and 69 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3939754\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance findings in placenta accreta include (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81005 graphicRef61154 \" href=\"UTD.htm?37/34/38441\">",
"     image 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uterine bulging into the bladder",
"     </li>",
"     <li>",
"      Heterogeneous signal intensity within the placenta",
"     </li>",
"     <li>",
"      Presence of intraplacental bands on the T2W imaging",
"     </li>",
"     <li>",
"      Abnormal placental vascularity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gadolinium, which would improve diagnostic performance, is generally avoided in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H26949515#H26949515\">",
"     \"Diagnostic imaging procedures during pregnancy\", section on 'Gadolinium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Magnetic resonance imaging can be more useful than ultrasound in two clinical scenarios: (1) evaluation of a possible posterior placenta accreta because the bladder cannot be used to help clarify the placental-myometrial interface, and (2) assessment of the depth of myometrial and parametrial involvement, and, if the placenta is anterior, bladder involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 300 patients with sonographic evidence of placenta accreta, subsequent magnetic resonance accurately characterized the level and topography of invasion in 97.7 percent, with four false positives for placenta percreta (1.3 percent) and three false negatives for placental invasion (1 percent); 11 cases were reclassified as placenta previa without invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/35\">",
"     35",
"    </a>",
"    ]. Magnetic resonance led to modifications in clinical management, such as use of prophylactic ureteral stent catheterization, in a substantial number of patients and significantly increased the number of women considered candidates for a conservative surgical procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3940147\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3940420\">",
"    <span class=\"h3\">",
"     Elevated maternal serum alpha-fetoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several series and case reports have reported an association between placenta accreta and otherwise unexplained elevations in second trimester maternal serum alpha-fetoprotein (MSAFP) concentration (&gt;2 or 2.5 multiples of the median [MOM]) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Although an elevated MSAFP level supports an ultrasound-based diagnosis of placenta accreta, it is an inconsistent finding and is not useful by itself for diagnosis of accreta. Moreover, a normal MSAFP does not exclude the diagnosis.",
"   </p>",
"   <p>",
"    The following examples illustrate these findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 9 of 20 women (45 percent) with placenta",
"      <span class=\"nowrap\">",
"       accreta/percreta/increta",
"      </span>",
"      had second trimester MSAFP values &ge;2.5 multiples of the median [MOMS] [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, 5 of 11 women (45 percent) with placenta",
"      <span class=\"nowrap\">",
"       accreta/percreta/increta",
"      </span>",
"      had second trimester MSAFP values &gt;2 MOMs [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third study of feasibility of Down syndrome serum screening in an Asian population noted that women with second-trimester MSAFP &ge;2.5 MOMs were at increased risk of having placenta accreta (odds ratio 8.3; 95% CI 1.8-39.3) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3940427\">",
"    <span class=\"h3\">",
"     Hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta percreta with bladder invasion can cause hematuria during pregnancy. A literature review including 54 cases of placenta percreta invading the bladder reported that",
"    <span class=\"nowrap\">",
"     17/54",
"    </span>",
"    were associated with hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/39\">",
"     39",
"    </a>",
"    ]. Cystoscopy was done in 12 patients, but was not useful for making a preoperative diagnosis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20157660\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum histological findings show placental villi anchored directly on, or invading into or through, the myometrium, without an intervening decidual plate. The placenta is characterized as an accreta (",
"    <a class=\"graphic graphic_picture graphicRef60800 \" href=\"UTD.htm?24/49/25369\">",
"     picture 1",
"    </a>",
"    ), increta (",
"    <a class=\"graphic graphic_picture graphicRef73597 \" href=\"UTD.htm?32/37/33366\">",
"     picture 2",
"    </a>",
"    ), or percreta, depending on the depth of myometrial invasion (superficial, deep, or penetrating the entire uterine wall). The diagnosis of focal accreta may be confirmed in the absence of hysterectomy by visualization of these findings in uterine curettings or in fragments of myometrium adherent to the placenta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis of placenta accreta is typically based upon the presence of characteristic findings on ultrasound examination. (See",
"    <a class=\"local\" href=\"#H3939740\">",
"     'Ultrasonography'",
"    </a>",
"    above.) Postnatal diagnosis is based on histological examination of the placenta or the placenta and uterus. (See",
"    <a class=\"local\" href=\"#H20157660\">",
"     'Histology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    No single diagnostic modality determines the prenatal diagnosis of placenta accreta with absolute accuracy. The diagnosis is highly likely in patients with placenta previa or a low lying placenta after one or more previous cesarean deliveries with imaging studies suggestive of abnormal implantation. The diagnosis can be reasonably excluded when imaging studies suggest normal placental implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20157587\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a placenta previa or a low anterior placenta and prior uterine surgery should have thorough sonographic evaluation of the interface between the placenta and myometrium between about 18 and 24 weeks of gestation. At this gestational age, the diagnosis can be made or excluded in virtually all cases. Color flow Doppler can help support a sonographic diagnosis of placenta accreta. Magnetic resonance imaging can be useful when the ultrasound findings are uncertain. (See",
"    <a class=\"local\" href=\"#H3939754\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If placenta accreta or worse is suspected, the patient and her family can be counseled about the suspected placental abnormality and an appropriate delivery plan can be developed.",
"   </p>",
"   <p>",
"    Prenatal diagnosis appears to improve outcome. In two retrospective series, women with predelivery diagnosis of accreta had significantly lower blood loss and transfusion requirements than women in whom the accreta was diagnosed during cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8311/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15006693\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In placenta accreta, the anchoring villi attach to the myometrium; in placenta increta, the villi invade into the myometrium; and in placenta percreta, the villi penetrate to or through the uterine serosa and may invade surrounding organs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important risk factor for placenta accreta is placenta previa after a prior cesarean delivery. Placenta accreta occurs in 11 to 25 percent of women with a placenta previa and one previous cesarean delivery. (See",
"      <a class=\"local\" href=\"#H3937600\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ideally, placenta accreta is first suspected because of findings on obstetrical ultrasound examination while the patient is asymptomatic. (See",
"      <a class=\"local\" href=\"#H3939541\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first clinical manifestation of placenta accreta is usually profuse, life-threatening hemorrhage that occurs at the time of attempted manual placental separation. Part or all of the placenta remains strongly adherent to the uterine cavity, and no plane of separation can be developed. Accordingly, it is important to recognize the risk factors and attempt to make a prenatal diagnosis. (See",
"      <a class=\"local\" href=\"#H3939541\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Placenta percreta with bladder invasion can cause hematuria. (See",
"      <a class=\"local\" href=\"#H3940427\">",
"       'Hematuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prenatal diagnosis of placenta accreta is based upon the presence of characteristic findings on ultrasound examination (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63825 \" href=\"UTD.htm?41/8/42115\">",
"       image 1",
"      </a>",
"      ). Color flow Doppler can help support a sonographic diagnosis. A normal image of placental implantation is rarely associated with placental invasion. (See",
"      <a class=\"local\" href=\"#H3939740\">",
"       'Ultrasonography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3939747\">",
"       'Color Doppler'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging is an adjunctive diagnostic tool when the diagnosis is uncertain, the placenta is posterior, or to gauge the depth of placental invasion. (See",
"      <a class=\"local\" href=\"#H3939754\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20157587\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/1\">",
"      Tantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta 2008; 29:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/2\">",
"      Miller DA, Chollet JA, Goodwin TM. Clinical risk factors for placenta previa-placenta accreta. Am J Obstet Gynecol 1997; 177:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/3\">",
"      Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol 2005; 192:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/4\">",
"      Read JA, Cotton DB, Miller FC. Placenta accreta: changing clinical aspects and outcome. Obstet Gynecol 1980; 56:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/5\">",
"      Khong TY. The pathology of placenta accreta, a worldwide epidemic. J Clin Pathol 2008; 61:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/6\">",
"      Jauniaux E, Jurkovic D. Placenta accreta: pathogenesis of a 20th century iatrogenic uterine disease. Placenta 2012; 33:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/7\">",
"      Clark SL, Koonings PP, Phelan JP. Placenta previa/accreta and prior cesarean section. Obstet Gynecol 1985; 66:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/8\">",
"      Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107:1226.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Consensus Development Conference Statement. NIH Consensus Development Conference: Vaginal Birth After Cesarean: New Insights. March 8&ndash;10, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/10\">",
"      Khong TY, Healy DL, McCloud PI. Pregnancies complicated by abnormally adherent placenta and sex ratio at birth. BMJ 1991; 302:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/11\">",
"      James WH. Sex ratios of offspring and the causes of placental pathology. Hum Reprod 1995; 10:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/12\">",
"      Zelop CM, Harlow BL, Frigoletto FD Jr, et al. Emergency peripartum hysterectomy. Am J Obstet Gynecol 1993; 168:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/13\">",
"      Glaze S, Ekwalanga P, Roberts G, et al. Peripartum hysterectomy: 1999 to 2006. Obstet Gynecol 2008; 111:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/14\">",
"      Gielchinsky Y, Mankuta D, Rojansky N, et al. Perinatal outcome of pregnancies complicated by placenta accreta. Obstet Gynecol 2004; 104:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/15\">",
"      Seet EL, Kay HH, Wu S, Terplan M. Placenta accreta: depth of invasion and neonatal outcomes. J Matern Fetal Neonatal Med 2012; 25:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/16\">",
"      O'Brien JM, Barton JR, Donaldson ES. The management of placenta percreta: conservative and operative strategies. Am J Obstet Gynecol 1996; 175:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/17\">",
"      Comstock CH. Antenatal diagnosis of placenta accreta: a review. Ultrasound Obstet Gynecol 2005; 26:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/18\">",
"      Warshak CR, Eskander R, Hull AD, et al. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta. Obstet Gynecol 2006; 108:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/19\">",
"      Chou MM, Ho ES, Lee YH. Prenatal diagnosis of placenta previa accreta by transabdominal color Doppler ultrasound. Ultrasound Obstet Gynecol 2000; 15:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/20\">",
"      Esakoff TF, Sparks TN, Kaimal AJ, et al. Diagnosis and morbidity of placenta accreta. Ultrasound Obstet Gynecol 2011; 37:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/21\">",
"      Dwyer BK, Belogolovkin V, Tran L, et al. Prenatal diagnosis of placenta accreta: sonography or magnetic resonance imaging? J Ultrasound Med 2008; 27:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/22\">",
"      Comstock CH, Love JJ Jr, Bronsteen RA, et al. Sonographic detection of placenta accreta in the second and third trimesters of pregnancy. Am J Obstet Gynecol 2004; 190:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/23\">",
"      Finberg HJ, Williams JW. Placenta accreta: prospective sonographic diagnosis in patients with placenta previa and prior cesarean section. J Ultrasound Med 1992; 11:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/24\">",
"      Comstock CH, Lee W, Vettraino IM, Bronsteen RA. The early sonographic appearance of placenta accreta. J Ultrasound Med 2003; 22:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/25\">",
"      Stirnemann JJ, Mousty E, Chalouhi G, et al. Screening for placenta accreta at 11-14 weeks of gestation. Am J Obstet Gynecol 2011; 205:547.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/26\">",
"      Ballas J, Pretorius D, Hull AD, et al. Identifying sonographic markers for placenta accreta in the first trimester. J Ultrasound Med 2012; 31:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/27\">",
"      Shih JC, Palacios Jaraquemada JM, Su YN, et al. Role of three-dimensional power Doppler in the antenatal diagnosis of placenta accreta: comparison with gray-scale and color Doppler techniques. Ultrasound Obstet Gynecol 2009; 33:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/28\">",
"      Cal&igrave; G, Giambanco L, Puccio G, Forlani F. Morbidly adherent placenta: evaluation of ultrasound diagnostic criteria and differentiation of placenta accreta from percreta. Ultrasound Obstet Gynecol 2013; 41:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/29\">",
"      Twickler DM, Lucas MJ, Balis AB, et al. Color flow mapping for myometrial invasion in women with a prior cesarean delivery. J Matern Fetal Med 2000; 9:330.",
"     </a>",
"    </li>",
"    <li>",
"     Grosvenor, A, Silver, R, Porter, TF, Zempolich, K. Optimal Management of Placenta Accreta. Am J Obste Gynecol 2007; 195. Abstr No. 238. p. S82.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/31\">",
"      Lax A, Prince MR, Mennitt KW, et al. The value of specific MRI features in the evaluation of suspected placental invasion. Magn Reson Imaging 2007; 25:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/32\">",
"      Derman AY, Nikac V, Haberman S, et al. MRI of placenta accreta: a new imaging perspective. AJR Am J Roentgenol 2011; 197:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/33\">",
"      Maldjian C, Adam R, Pelosi M, et al. MRI appearance of placenta percreta and placenta accreta. Magn Reson Imaging 1999; 17:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/34\">",
"      Kirkinen P, Helin-Martikainen HL, Vanninen R, Partanen K. Placenta accreta: imaging by gray-scale and contrast-enhanced color Doppler sonography and magnetic resonance imaging. J Clin Ultrasound 1998; 26:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/35\">",
"      Palacios Jaraquemada JM, Bruno CH. Magnetic resonance imaging in 300 cases of placenta accreta: surgical correlation of new findings. Acta Obstet Gynecol Scand 2005; 84:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/36\">",
"      Kupferminc MJ, Tamura RK, Wigton TR, et al. Placenta accreta is associated with elevated maternal serum alpha-fetoprotein. Obstet Gynecol 1993; 82:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/37\">",
"      Hung TH, Shau WY, Hsieh CC, et al. Risk factors for placenta accreta. Obstet Gynecol 1999; 93:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/38\">",
"      Zelop C, Nadel A, Frigoletto FD Jr, et al. Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein. Obstet Gynecol 1992; 80:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/39\">",
"      Washecka R, Behling A. Urologic complications of placenta percreta invading the urinary bladder: a case report and review of the literature. Hawaii Med J 2002; 61:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/40\">",
"      Warshak CR, Ramos GA, Eskander R, et al. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstet Gynecol 2010; 115:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8311/abstract/41\">",
"      Tikkanen M, Paavonen J, Loukovaara M, Stefanovic V. Antenatal diagnosis of placenta accreta leads to reduced blood loss. Acta Obstet Gynecol Scand 2011; 90:1140.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6759 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8311=[""].join("\n");
var outline_f8_7_8311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15006693\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3937332\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3937600\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3939541\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15006491\">",
"      Sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3939548\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3939740\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27505539\">",
"      Three-dimensional ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3939747\">",
"      Color Doppler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3939754\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3940147\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3940420\">",
"      - Elevated maternal serum alpha-fetoprotein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3940427\">",
"      - Hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20157660\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20157587\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15006693\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6759\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6759|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/8/42115\" title=\"diagnostic image 1\">",
"      Sonogram of placenta accreta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/54/20326\" title=\"diagnostic image 2\">",
"      Ultrasound and Doppler images of placenta accreta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/58/41891\" title=\"diagnostic image 3A\">",
"      MR normal placenta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/54/35686\" title=\"diagnostic image 3B\">",
"      MR placenta accreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6759|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/49/25369\" title=\"picture 1\">",
"      Placenta accreta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/37/33366\" title=\"picture 2\">",
"      Placenta increta",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41256?source=related_link\">",
"      Placental development and physiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_7_8312="Condylomata acuminata (anogenital warts) in children";
var content_f8_7_8312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Condylomata acuminata (anogenital warts) in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/7/8312/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8312/contributors\">",
"     Latanya T Benjamin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/7/8312/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8312/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/7/8312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8312/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/7/8312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H276633438\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condylomata acuminata (also known as anogenital warts or venereal warts) are manifestations of human papillomavirus (HPV) infection that typically appear as flesh-colored or hyperpigmented verrucous papules or plaques in the perianal or genital region. Condyloma acuminatum may develop as a result of the acquisition of HPV infection via sexual or nonsexual means. In very young children, transmission of HPV via nonsexual contact may be the most common precipitator of these lesions.",
"   </p>",
"   <p>",
"    The transmission, diagnosis, and management of condyloma acuminatum in children will be discussed here. Condyloma acuminatum in adults and cutaneous warts are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27178?source=see_link\">",
"     \"Treatment of vulvar and vaginal warts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26249?source=see_link\">",
"     \"Cutaneous warts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4079450\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic data on condyloma acuminatum in children are limited, and the prevalence of this condition in infants and children is unknown. Estimates of the average age at which children present with condyloma acuminatum range between 2.8 and 5.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/1\">",
"     1",
"    </a>",
"    ]. A female predominance is suggested by several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38933903\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condyloma acuminatum is caused by infection with human papillomavirus (HPV), a double-stranded DNA virus with more than 100 serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/2\">",
"     2",
"    </a>",
"    ]. Although condyloma acuminatum in adults is commonly caused by HPV 6 and 11, the HPV types detected in lesions from children are more variable. HPV types associated with cutaneous warts (eg, HPV 1 to 4 and others) are frequently detected in anogenital lesions from children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. In one review of approximately 200 pediatric cases of condylomata acuminata in which HPV DNA was detected, HPV 6 or 11 was detected in 56 percent, HPV 1 to 4 in 12 percent, and HPV 16 or 18 in 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/5\">",
"     5",
"    </a>",
"    ]. A separate series in which 40 children under the age of 12 with condyloma acuminatum underwent wart excision and HPV testing found that HPV types 6, 11,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    16 were present in only one-third of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"     \"Epidemiology of human papillomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38935885\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of sexual abuse is a major concern in the evaluation of children with condyloma acuminatum. However, other modes of viral transmission may account for the majority of pediatric cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/6\">",
"     6",
"    </a>",
"    ]. The potential methods for HPV acquisition in children are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Heteroinoculation",
"      </strong>",
"      &ndash; Transmission of HPV may occur during nonsexual contact with a caregiver, such as bathing or diaper changing.",
"     </li>",
"     <li>",
"      <strong>",
"       Autoinoculation",
"      </strong>",
"      &ndash; Children may acquire anogenital lesions from self due to transmission of HPV from other cutaneous or mucosal sites of infection.",
"     </li>",
"     <li>",
"      <strong>",
"       Sexual abuse",
"      </strong>",
"      &ndash; Estimates of the proportion of children with condyloma acuminatum who have been sexually abused vary widely, ranging from &lt;10 percent to 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/4,6\">",
"       4,6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The likelihood of sexual abuse as the cause of HPV infection increases as children age [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/2,6,7\">",
"       2,6,7",
"      </a>",
"      ]. In a retrospective study of 55 children under the age of 13 with condyloma acuminatum who were evaluated for sexual abuse, children between the ages of four and eight years were 2.9 times more likely than children under the age of four years to have been sexually abused (95% CI 0.7-12.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/6\">",
"       6",
"      </a>",
"      ]. In addition, children between the ages of 8 and 12 were 12.1 times more likely than the youngest group of children to have been sexually abused (95% CI 2.3-63.6).",
"     </li>",
"     <li>",
"      <strong>",
"       Perinatal or prenatal transmission",
"      </strong>",
"      &ndash; HPV infection in newborn infants may occur during vaginal delivery through an infected maternal genital tract. In addition, HPV DNA has been detected in amniotic fluid and umbilical cord blood, suggesting that ascension of the infection into the uterus and hematogenous dissemination of the virus may be routes of prenatal HPV transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. A report of perianal warts in a neonate supports the possibility of prenatal HPV transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Transmission via fomites",
"      </strong>",
"      &ndash; Transmission of HPV via fomites, such as contaminated towels or underwear, has been proposed as a method of HPV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/1,11\">",
"       1,11",
"      </a>",
"      ]. However, fomites are likely to account for very few cases of condyloma acuminatum in children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The identification of the route of virus acquisition in children with condyloma acuminatum is complicated by the variable incubation period of HPV. Data in adults indicate that a typical incubation period ranges from three weeks to eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/11\">",
"     11",
"    </a>",
"    ]. The average duration of the incubation period is three months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, serotyping is not a reliable method for determining the mode of HPV acquisition in children. The detection of a primarily cutaneous subtype of HPV is insufficient to rule out sexual abuse. As an example, cutaneous HPV infection on the hand of a sexual perpetrator could be transmitted to the anogenital region of a child through manual-genital abuse. Moreover, the HPV serotypes most commonly associated with sexually transmitted condyloma acuminatum in adults (eg, HPV 6 and 11) are detected with variable frequency in condyloma acuminatum in children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/2,5,7\">",
"     2,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276633452\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condylomata acuminata initially appear as flesh-colored, pink, or brown soft moist papules that are a few millimeters in diameter (",
"    <a class=\"graphic graphic_picture graphicRef83496 graphicRef83497 \" href=\"UTD.htm?38/15/39160\">",
"     picture 1A-B",
"    </a>",
"    ). Over the course of weeks to months, the papules may coalesce into larger plaques that often demonstrate a \"cauliflower appearance\" (",
"    <a class=\"graphic graphic_picture graphicRef83498 \" href=\"UTD.htm?10/23/10612\">",
"     picture 2",
"    </a>",
"    ). In boys, condylomata acuminata are most commonly detected in the perianal area and are less frequently found on the penile shaft. Girls may present with lesions on the perianal area, vulva, hymen, vaginal vestibule,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    periurethral areas. Anogenital warts may also occur on the internal mucosal surfaces of vagina or rectum.",
"   </p>",
"   <p>",
"    Although occasional lesions are pruritic or painful, condyloma acuminatum is usually asymptomatic. Rarely, bleeding occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38934368\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data are available on the natural history of condyloma acuminatum in children, but there is evidence that many infections resolve spontaneously within a few years. In a retrospective and prospective study of 41 children with condyloma acuminatum, spontaneous resolution occurred within five years in six of eight children who never received treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/3\">",
"     3",
"    </a>",
"    ]. The average duration of these lesions prior to resolution was nine months (range 5 to 12 months). Among the 33 children who were treated, 9 (27 percent) had resolution that appeared attributable to treatment and 16 (48 percent) had resolution that appeared to be spontaneous (the disappearance of condylomata acuminata failed to correlate with the timing of treatment). The average duration of lesions in the group with apparent spontaneous resolution was 25 months (range 2 to 58 months).",
"   </p>",
"   <p>",
"    Similar to many other infections, immunosuppression influences the course and prognosis of condyloma acuminatum. Immunosuppressed children may develop extensive lesions that are challenging to treat [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38934039\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of condyloma acuminatum is usually made via clinical examination. Biopsies are rarely required, and are usually reserved for patients in whom the diagnosis is uncertain or when the warts demonstrate atypical features, such as ulceration. Common histopathologic features of condyloma acuminatum include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Marked acanthosis with some papillomatosis and hyperkeratosis",
"     </li>",
"     <li>",
"      Vacuolated koilocytes (less prominent than other viral warts)",
"     </li>",
"     <li>",
"      Coarse keratohyaline granules",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Viral serotyping can be performed by polymerase chain reaction (PCR) or nucleic acid hybridization assays [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/14\">",
"     14",
"    </a>",
"    ]. However, viral serotyping is not routinely performed since it is not necessary for diagnosis and is not reliable for identifying the source of infection. (See",
"    <a class=\"local\" href=\"#H38935885\">",
"     'Transmission'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38936389\">",
"    <span class=\"h2\">",
"     Assessment for sexual abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is likely that many children with condyloma acuminatum acquire the disorder through nonsexual means, the possibility of sexual abuse warrants serious consideration during patient evaluation. Children under four years of age with condyloma acuminatum are less likely to be victims of sexual abuse than older children, but the possibility of sexual abuse cannot be definitively excluded based upon age. (See",
"    <a class=\"local\" href=\"#H38935885\">",
"     'Transmission'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Interviews with the caregivers and the child (if old enough to participate), as well as clinical or laboratory examination to evaluate for sexual abuse and other sexually transmitted infections are important components of the patient assessment. If any findings suggestive of sexual abuse are detected, reporting to child protective services or legal authorities in accordance with local policies is indicated.",
"   </p>",
"   <p>",
"    Due to the greater likelihood of sexual abuse as a precipitator of condyloma acuminatum in older children, a higher level of suspicion should exist for children over the age of four [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/1\">",
"     1",
"    </a>",
"    ]. Exceptions include adolescents who report consensual sexual activity and immunosuppressed children with multiple nongenital warts who lack other findings suggestive of abuse.",
"   </p>",
"   <p>",
"    We agree with the following approach to the initial evaluation for sexual abuse in children with condyloma acuminatum [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interview of primary caregivers to determine whether the child may be at risk for sexual abuse and to establish the presence of cutaneous or anogenital warts in the caregivers or other family members",
"     </li>",
"     <li>",
"      Interview of the child regarding sexual abuse by a professional trained in this field (provided the child is old enough to participate - usually three to four years of age)",
"     </li>",
"     <li>",
"      Assessment for signs or symptoms that may accompany a history of sexual abuse (eg, nightmares, advanced sexual knowledge, sexual behavior with peers)",
"     </li>",
"     <li>",
"      Physical examination for evidence of physical or sexual abuse, including magnified examination of genital and anal sites looking for signs of acute trauma (hymenal bruising, petechiae, anal tears) or chronic trauma (absent hymen at the posterior hymenal rim, anogenital scarring)",
"     </li>",
"     <li>",
"      Screening for other sexually transmitted diseases as determined appropriate by the scenario (eg, gonorrhea, chlamydia, trichomoniasis, human immunodeficiency virus, hepatitis B and C, syphilis)",
"     </li>",
"     <li>",
"      Referral to a child abuse specialist if the clinicians involved are not comfortable or adequately trained to perform this assessment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation and reporting of sexual abuse in children is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link\">",
"     \"Child abuse: Social and medicolegal issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276633466\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condylomata acuminata share clinical features with several disorders. Examples of disorders to consider in the differential diagnosis are provided below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Molluscum contagiosum",
"      </strong>",
"      &ndash; Molluscum contagiosum is a cutaneous viral infection commonly seen in children. The recognition of round, smooth, skin-colored papules with central umbilication supports a diagnosis molluscum contagiosum (",
"      <a class=\"graphic graphic_picture graphicRef83521 \" href=\"UTD.htm?21/21/21842\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=see_link\">",
"       \"Molluscum contagiosum\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pyramidal perianal papules",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Pyramidal perianal papules (infantile perianal pyramidal protrusions) are solitary, fleshy perianal protrusions that occur in prepubertal children (",
"      <a class=\"graphic graphic_picture graphicRef62735 \" href=\"UTD.htm?14/57/15248\">",
"       picture 4",
"      </a>",
"      ). These lesions are found anterior to the anus and are less than 2 cm in diameter. Female children are most frequently affected. Pyramidal perianal papules usually resolve spontaneously with time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=see_link&amp;anchor=H11#H11\">",
"       \"The pediatric physical examination: The perineum\", section on 'Anus and rectum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Condylomata lata of syphilis",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Condylomata lata of secondary syphilis are highly infectious, moist papules and small plaques that may develop in the anogenital region (",
"      <a class=\"graphic graphic_picture graphicRef83522 \" href=\"UTD.htm?1/45/1749\">",
"       picture 5",
"      </a>",
"      ). Serologic testing is useful for diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H14#H14\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Rash'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H24#H24\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Epidermal nevi",
"      </strong>",
"      &ndash; Epidermal nevi are uncommon skin lesions that present at birth or in early childhood as skin-colored to hyperpigmented verrucous plaques (",
"      <a class=\"graphic graphic_picture graphicRef86582 \" href=\"UTD.htm?29/32/30209\">",
"       picture 6",
"      </a>",
"      ). A linear distribution or a distribution that follows Blaschko&rsquo;s lines (",
"      <a class=\"graphic graphic_figure graphicRef57219 \" href=\"UTD.htm?31/60/32710\">",
"       figure 1",
"      </a>",
"      ) is suggestive of an epidermal nevus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276633487\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple therapies have been utilized for the treatment of condyloma acuminatum in children and adults. The therapeutic options consist of interventions that mechanically or chemically destroy infected tissue or that upregulate the host immune response against infected cells.",
"   </p>",
"   <p>",
"    Since many cases of condyloma acuminatum in children resolve spontaneously within a few years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/3,14\">",
"     3,14",
"    </a>",
"    ] and the response to treatment is variable, treatment of condyloma acuminatum is optional. Nonintervention with a &ldquo;wait and see&rdquo; approach is frequently utilized for the management of condyloma acuminatum in children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Treatment is preferred over nonintervention when patients develop symptoms (eg, pruritus, bleeding, or pain) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/1\">",
"     1",
"    </a>",
"    ] or when concern over the appearance of lesions causes emotional distress in the child or is socially detrimental. In addition, warts that persist for more than two years may be less likely to resolve spontaneously than younger lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H38934368\">",
"     'Clinical course'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38934442\">",
"    <span class=\"h2\">",
"     Therapeutic options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple therapies (eg, topical cytotoxic agents, topical and systemic immune modulators, cryotherapy, electrocauterization, lasers, and surgery) have been utilized for the treatment of condyloma acuminatum. However, no single treatment is consistently effective and lesion recurrence often occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link&amp;anchor=H10#H10\">",
"     \"Condylomata acuminata (anogenital warts)\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ability of the child to tolerate treatment strongly influences treatment selection. Young children are often fearful of painful treatments such as cryotherapy, and general anesthesia is typically required for surgical and ablative laser therapy. Thus, topical therapy is frequently utilized as the initial treatment for condyloma acuminatum in children.",
"   </p>",
"   <p>",
"    The most common topical agents utilized for pediatric condyloma acuminatum are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    and podophyllotoxin. Data on the efficacy and safety of these and other therapies for condyloma acuminatum in children are limited. In a randomized trial of 45 adults with condyloma acuminatum that directly compared imiquimod 5% cream (three times per week for up to 16 weeks) and podophyllotoxin 0.5% solution (three days per week for up to four weeks), the efficacy of these agents was similar [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/15\">",
"     15",
"    </a>",
"    ]. Surgical and laser therapy are typically reserved for children with large or recalcitrant lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38934809\">",
"    <span class=\"h3\">",
"     Imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    5% cream and a newer formulation, imiquimod 3.75% cream, are topical immune response modifiers for which randomized trials have demonstrated efficacy for the treatment of external genital and perianal warts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Imiquimod 5% cream is applied three times weekly on nonconsecutive days for a maximum of 16 weeks. The 3.75% formulation is applied once daily for up to eight weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link&amp;anchor=H16#H16\">",
"     \"Condylomata acuminata (anogenital warts)\", section on 'Imiquimod'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data are limited on the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    in children under the age of 12 years. The use of imiquimod in children is supported by several case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/19-23\">",
"     19-23",
"    </a>",
"    ] and a retrospective study in which eight children with anogenital warts (six under the age of five years) were treated with imiquimod three times per week for two to four months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/24\">",
"     24",
"    </a>",
"    ]. Six children (75 percent) in the retrospective study had clearance of warts that persisted for at least 6 to 12 months. Imiquimod has also been well-tolerated by children treated with this agent for molluscum contagiosum [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=see_link&amp;anchor=H421647#H421647\">",
"     \"Molluscum contagiosum\", section on 'Imiquimod'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common side effect of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    is local skin irritation. In our experience, this occurs most frequently at sites of skin occlusion. Infrequently, flu-like symptoms may occur during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38934730\">",
"    <span class=\"h3\">",
"     Podophyllotoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Podophyllotoxin is an antimitotic agent that is effective for the treatment of condyloma acuminatum [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Podophyllotoxin is commercially available as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/34/23074?source=see_link\">",
"     podofilox",
"    </a>",
"    0.5% solution and gel (typically applied twice daily for three consecutive days per week for up to four weeks) and as podophyllin 25% liquid, which must be applied in the office by a clinician. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link&amp;anchor=H12#H12\">",
"     \"Condylomata acuminata (anogenital warts)\", section on 'Podophyllin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the efficacy of podophyllotoxin for condyloma acuminatum is supported by randomized trials performed in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/15,28-31\">",
"     15,28-31",
"    </a>",
"    ], data on the efficacy and safety of podophyllotoxin in children are limited. In a retrospective study of 17 children with condyloma acuminatum, including 11 children who were under the age of five years, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/34/23074?source=see_link\">",
"     podofilox",
"    </a>",
"    0.5% gel for one to four months (initially once weekly and increased as tolerated to twice daily for three consecutive days per week) led to clearance of lesions for at least four months in 88 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/24\">",
"     24",
"    </a>",
"    ]. One child failed to respond to treatment and a second child was unable to tolerate therapy.",
"   </p>",
"   <p>",
"    The comparative efficacy of podophyllotoxin 0.5% and podophyllin 25% was evaluated in a randomized trial of 358 adults that compared treatment with podophyllotoxin 0.5% solution, podophyllotoxin 0.15% cream, and podophyllin 25% liquid [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/28\">",
"     28",
"    </a>",
"    ]. Podophyllotoxin 0.5% solution was more effective than podophyllin 25% liquid for the clearance of all warts (84 versus 62 percent of patients had clearance of lesions). Relapse was common after the discontinuation of all treatments.",
"   </p>",
"   <p>",
"    Local skin irritation, discomfort, and ulceration are potential adverse effects of podophyllin therapy. Relapse is common after the discontinuation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38934744\">",
"    <span class=\"h3\">",
"     Surgical and laser therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical and laser procedures are usually reserved for children with extensive or large warts (eg, 1 cm or greater) or warts recalcitrant to topical therapy. Options for surgical treatment include cryotherapy, electrodesiccation, carbon dioxide laser ablation, and surgical debulking or excision. Clearance of childhood perianal warts has also been reported after treatment with a pulsed dye laser [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to medical therapy, warts may recur after destructive procedures. Additional information on these procedures is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link&amp;anchor=H18#H18\">",
"     \"Condylomata acuminata (anogenital warts)\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38934751\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other treatments have been utilized for the treatment of condyloma acuminatum in adults, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7794?source=see_link\">",
"     trichloroacetic acid",
"    </a>",
"    , 5-fluorouracil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15923?source=see_link\">",
"     sinecatechins",
"    </a>",
"    , topical",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/34/14886?source=see_link\">",
"     cidofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/58/43943?source=see_link\">",
"     cimetidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], and additional agents. The efficacy and safety of these treatments in children has not been established. These treatments are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link&amp;anchor=H10#H10\">",
"     \"Condylomata acuminata (anogenital warts)\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38934759\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HPV infection has been associated with increased risk for cervical, anal, and penile cancer, the impact of childhood HPV infection on the risk for these malignancies is unknown (",
"    <a class=\"graphic graphic_table graphicRef76394 \" href=\"UTD.htm?0/27/443\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8312/abstract/11,35,36\">",
"     11,35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link&amp;anchor=H7674829#H7674829\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link&amp;anchor=H4#H4\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38762?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features, staging, and treatment of anal cancer\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link&amp;anchor=H9#H9\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term, periodic follow-up for signs or symptoms of anal cancer is recommended for children with anogenital warts that extend beyond the anal verge and involve the mucosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38762?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features, staging, and treatment of anal cancer\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link&amp;anchor=H9#H9\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135472473\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance of autoinoculation or heteroinoculation of HPV into the anogenital region is the primary mode of prevention of condyloma acuminatum. The quadrivalent HPV vaccine, which protects against HPV 6, 11, 16, and 18 is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38936913\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Condylomata acuminata (also known as anogenital warts or venereal warts) are cutaneous lesions caused by infection with human papillomavirus (HPV). Both mucosal and cutaneous HPV serotypes can lead to the development of condyloma acuminatum in children. (See",
"      <a class=\"local\" href=\"#H38933903\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Condyloma acuminatum in children may arise from HPV transmission through a variety of mechanisms. Although the possibility of sexual abuse is a major concern, many children, particularly those under the age of four years, acquire HPV infection through nonsexual interactions. (See",
"      <a class=\"local\" href=\"#H38935885\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Condyloma acuminatum usually begins as single or multiple flesh-colored, pink, or brown papules (",
"      <a class=\"graphic graphic_picture graphicRef83496 graphicRef83497 \" href=\"UTD.htm?38/15/39160\">",
"       picture 1A-B",
"      </a>",
"      ). As the infection progresses, lesions may develop into large verrucous plaques with a &ldquo;cauliflower-like&rdquo; appearance (",
"      <a class=\"graphic graphic_picture graphicRef83498 \" href=\"UTD.htm?10/23/10612\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H276633452\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spontaneous resolution of condyloma acuminatum is possible, and many infections resolve within a few years. Lesions that persist for more than two years or develop in immunosuppressed individuals may be less likely to resolve without treatment. (See",
"      <a class=\"local\" href=\"#H38934368\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of sexual abuse should be considered in all children who present with condyloma acuminatum. Children over the age of four years are more likely to have a history of sexual abuse than younger children. The evaluation for sexual abuse typically begins with interviews with the caregivers and child, a complete physical examination, and screening for other sexually transmitted diseases. (See",
"      <a class=\"local\" href=\"#H38936389\">",
"       'Assessment for sexual abuse'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"       \"Evaluation of sexual abuse in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment is optional for children with condylomata acuminata since lesions may resolve spontaneously. Warts that persist for longer than two years may be less likely than earlier lesions to resolve without treatment. (See",
"      <a class=\"local\" href=\"#H276633487\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since most condylomata acuminata in children resolve within a few years, treatment is not required for most children with asymptomatic lesions. For children with symptomatic lesions, lesions that fail to spontaneously resolve, immunosuppression, or lesions that lead to emotional distress or social problems, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      5% or 3.75% cream or podophyllotoxin 0.5% gel or solution (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Children with lesions recalcitrant to topical therapy may benefit from laser therapy or surgical procedures. (See",
"      <a class=\"local\" href=\"#H38934442\">",
"       'Therapeutic options'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link&amp;anchor=H18#H18\">",
"       \"Condylomata acuminata (anogenital warts)\", section on 'Surgery'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/1\">",
"      Sinclair KA, Woods CR, Sinal SH. Venereal warts in children. Pediatr Rev 2011; 32:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/2\">",
"      Marcoux D, Nadeau K, McCuaig C, et al. Pediatric anogenital warts: a 7-year review of children referred to a tertiary-care hospital in Montreal, Canada. Pediatr Dermatol 2006; 23:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/3\">",
"      Allen AL, Siegfried EC. The natural history of condyloma in children. J Am Acad Dermatol 1998; 39:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/4\">",
"      Stefanaki C, Barkas G, Valari M, et al. Condylomata acuminata in children. Pediatr Infect Dis J 2012; 31:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/5\">",
"      Syrj&auml;nen S. Current concepts on human papillomavirus infections in children. APMIS 2010; 118:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/6\">",
"      Sinclair KA, Woods CR, Kirse DJ, Sinal SH. Anogenital and respiratory tract human papillomavirus infections among children: age, gender, and potential transmission through sexual abuse. Pediatrics 2005; 116:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/7\">",
"      Unger ER, Fajman NN, Maloney EM, et al. Anogenital human papillomavirus in sexually abused and nonabused children: a multicenter study. Pediatrics 2011; 128:e658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/8\">",
"      Armbruster-Moraes E, Ioshimoto LM, Le&atilde;o E, Zugaib M. Presence of human papillomavirus DNA in amniotic fluids of pregnant women with cervical lesions. Gynecol Oncol 1994; 54:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/9\">",
"      Syrj&auml;nen S, Puranen M. Human papillomavirus infections in children: the potential role of maternal transmission. Crit Rev Oral Biol Med 2000; 11:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/10\">",
"      Tang CK, Shermeta DW, Wood C. Congenital condylomata acuminata. Am J Obstet Gynecol 1978; 131:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/11\">",
"      Jayasinghe Y, Garland SM. Genital warts in children: what do they mean? Arch Dis Child 2006; 91:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/12\">",
"      Chatterjee R, Bhattacharyya S, Biswas R, Das S. Giant condyloma acuminata in pediatric HIV. Indian Pediatr 2011; 48:62.",
"     </a>",
"    </li>",
"    <li>",
"     Weedon D. Viral diseases. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.515.",
"    </li>",
"    <li>",
"     Paller AS, Mancini AJ. Viral diseases of the skin. In: Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, Third edition, Elsevier Saunders, Philadelphia 2006. p.405.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/15\">",
"      Komericki P, Akkilic-Materna M, Strimitzer T, Aberer W. Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts. Sex Transm Dis 2011; 38:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/16\">",
"      Baker DA, Ferris DG, Martens MG, et al. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies. Infect Dis Obstet Gynecol 2011; 2011:806105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/17\">",
"      Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/18\">",
"      Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 1998; 134:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/19\">",
"      Masuko T, Fuchigami T, Inadomi T, et al. Effectiveness of imiquimod 5% cream for treatment of perianal warts in a 28-month-old child. Pediatr Int 2011; 53:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/20\">",
"      Campaner AB, Santos RE, Galv&atilde;o MA, et al. Effectiveness of imiquimod 5% cream for treatment of extensive anogenital warts in a seven-year-old child. Pediatr Infect Dis J 2007; 26:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/21\">",
"      Gruber PC, Wilkinson J. Successful treatment of perianal warts in a child with 5% imiquimod cream. J Dermatolog Treat 2001; 12:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/22\">",
"      Schaen L, Mercurio MG. Treatment of human papilloma virus in a 6-month-old infant with imiquimod 5% cream. Pediatr Dermatol 2001; 18:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/23\">",
"      Majewski S, Pniewski T, Malejczyk M, Jablonska S. Imiquimod is highly effective for extensive, hyperproliferative condyloma in children. Pediatr Dermatol 2003; 20:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/24\">",
"      Moresi JM, Herbert CR, Cohen BA. Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream. Pediatr Dermatol 2001; 18:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/25\">",
"      Theos AU, Cummins R, Silverberg NB, Paller AS. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. Cutis 2004; 74:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/26\">",
"      Longstaff E, von Krogh G. Condyloma eradication: self-therapy with 0.15-0.5% podophyllotoxin versus 20-25% podophyllin preparations--an integrated safety assessment. Regul Toxicol Pharmacol 2001; 33:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/27\">",
"      Xie FM, Zeng K, Chen ZL, et al. [Treatment of recurrent condyloma acuminatum with solid lipid nanoparticle gel containing podophyllotoxin: a randomized double-blinded, controlled clinical trial]. Nan Fang Yi Ke Da Xue Xue Bao 2007; 27:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/28\">",
"      Lacey CJ, Goodall RL, Tennvall GR, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003; 79:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/29\">",
"      Yan J, Chen SL, Wang HN, Wu TX. Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of condylomata acuminata. Dermatology 2006; 213:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/30\">",
"      Syed TA, Lundin S, Ahmad SA. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of condylomata acuminata in women. A placebo-controlled, double-blind study. Dermatology 1994; 189:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/31\">",
"      Hellberg D, Svarrer T, Nilsson S, Valentin J. Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution. Int J STD AIDS 1995; 6:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/32\">",
"      Tuncel A, G&ouml;rg&uuml; M, Ayhan M, et al. Treatment of anogenital warts by pulsed dye laser. Dermatol Surg 2002; 28:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/33\">",
"      Cohler M, Schaffer JV. Successful treatment of massive anogenital warts in a two-year-old boy with imiquimod and cimetidine immunotherapy. Pediatr Infect Dis J 2009; 28:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/34\">",
"      Franco I. Oral cimetidine for the management of genital and perigenital warts in children. J Urol 2000; 164:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/35\">",
"      Lee SH, McGregor DH, Kuziez MN. Malignant transformation of perianal condyloma acuminatum: a case report with review of the literature. Dis Colon Rectum 1981; 24:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8312/abstract/36\">",
"      Ejeckam GC, Idikio HA, Nayak V, Gardiner JP. Malignant transformation in an anal condyloma acuminatum. Can J Surg 1983; 26:170.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13732 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-259ED97FEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8312=[""].join("\n");
var outline_f8_7_8312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38936913\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276633438\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4079450\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38933903\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38935885\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276633452\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38934368\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38934039\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38936389\">",
"      Assessment for sexual abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276633466\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276633487\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38934442\">",
"      Therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38934809\">",
"      - Imiquimod",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38934730\">",
"      - Podophyllotoxin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38934744\">",
"      - Surgical and laser therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38934751\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38934759\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H135472473\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38936913\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13732\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13732|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/60/32710\" title=\"figure 1\">",
"      Lines of Blaschko",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13732|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/47/9971\" title=\"picture 1A\">",
"      Perianal condyloma acuminatum in child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/19/32052\" title=\"picture 1B\">",
"      Penile condyloma acuminatum in a child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/23/10612\" title=\"picture 2\">",
"      Condyloma acuminatum papules and plaques in a child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/21/21842\" title=\"picture 3\">",
"      Molluscum contagiosum pediatric genital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/57/15248\" title=\"picture 4\">",
"      Infantile perianal pyramidal protrusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/45/1749\" title=\"picture 5\">",
"      Condylomata lata of syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/32/30209\" title=\"picture 6\">",
"      Epidermal nevus - inguinal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13732|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/27/443\" title=\"table 1\">",
"      Risk of cervical CA with HPV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38762?source=related_link\">",
"      Clinical features, staging, and treatment of anal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26249?source=related_link\">",
"      Cutaneous warts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=related_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=related_link\">",
"      Molluscum contagiosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=related_link\">",
"      The pediatric physical examination: The perineum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27178?source=related_link\">",
"      Treatment of vulvar and vaginal warts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_7_8313="Interstitial lung disease in dermatomyositis and polymyositis: Treatment";
var content_f8_7_8313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interstitial lung disease in dermatomyositis and polymyositis: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/7/8313/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8313/contributors\">",
"     Paul F Dellaripa, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8313/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/7/8313/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8313/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8313/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/7/8313/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8313/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8313/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/7/8313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial lung disease (ILD) is a major cause of morbidity and mortality in dermatomyositis (DM) and polymyositis (PM). The clinical features and histopathologic appearance of ILD in DM and PM reflect the patterns of lung pathology associated with the idiopathic interstitial pneumonias, including nonspecific interstitial pneumonia, usual interstitial pneumonia, organizing pneumonia, and acute interstitial pneumonitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of interstitial lung disease associated with DM and PM will be reviewed here. The clinical manifestations, diagnosis, and differential diagnosis of interstitial lung disease in DM and PM and the management of myositis in DM and PM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2138?source=see_link\">",
"     \"Treatment and prognosis of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIATING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to initiate treatment of ILD in patients with DM or PM is usually based upon the severity of dyspnea and pulmonary function test (PFT) abnormalities, and also the need for treatment of the underlying myositis. Treatment of the myositis is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with radiographic ILD who are asymptomatic and have mild reductions in lung volumes and diffusing capacity, we suggest a period of observation with serial assessment of clinical status and PFTs. For patients with dyspnea and evidence of respiratory impairment on PFTs, immunosuppressive therapy is usually indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link&amp;anchor=H8#H8\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\", section on 'Pulmonary function tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids are the mainstay of treatment of ILD in patients with PM or DM, regardless of whether the predominant feature of the patient's illness is pneumonitis or myositis. When the specific form of ILD is determined to be nonspecific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), or is not specifically categorized, the initial regimen is typically the same as that used for the myositis alone (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    ideal body weight per day, to a maximum daily dose of 60 mg). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\", section on 'Systemic glucocorticoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link&amp;anchor=H3#H3\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\", section on 'Histopathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After one month,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is usually tapered to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for an additional two months, followed by further tapering dependent on the response to therapy. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Assessing the response and tapering therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with impending respiratory failure due to rapidly progressive interstitial pneumonitis are treated with high-dose intravenous glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1 gram daily for three days), followed by oral glucocorticoid therapy as noted above. A second immunosuppressive agent, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , is typically added, as described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\", section on 'Systemic glucocorticoids'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Cyclophosphamide'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with a clinical and histopathologic pattern of organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia or BOOP), glucocorticoid dosing and tapering would follow that for cryptogenic organizing pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link&amp;anchor=H12#H12\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been estimated that about 50 percent of patients with ILD and either DM or PM respond favorably to glucocorticoid therapy, although no controlled trials have been undertaken [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Clinical features suggesting a high rate of response to systemic glucocorticoids include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Younger age [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      PM rather than DM [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Organizing pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated serum CK levels [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ground glass or consolidative opacities rather than honeycombing on high resolution CT scan [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/3,8,9\">",
"       3,8,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A pattern of nonspecific interstitial pneumonia rather than usual interstitial pneumonia on lung biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/3,10\">",
"       3,10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ADDING A SECOND AGENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second immunosuppressive agent is often added to glucocorticoid therapy either for a glucocorticoid-sparing effect or because the ILD is more severe or progressive.",
"   </p>",
"   <p>",
"    In patients with mild to moderate ILD (eg, dyspnea on moderate to marked exertion and mild impairment on pulmonary function tests [PFTs]), glucocorticoids alone may be adequate therapy. However, many experts add a second immunosuppressive agent without waiting for a response to glucocorticoid therapy or a failure of tapering, although this choice has not been evaluated in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the high frequency of progressive disease in patients with amyopathic disease or the antisynthetase syndrome, we utilize a second agent to treat these patients, even when the ILD is mild.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of a specific agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, calcineurin inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) is guided by the severity of the patient's ILD, the relative toxicity of the agents, and the experience of the treating clinician with the various agents. The evidence supporting the different choices comes from case series and case reports, as comparative studies have not been performed.",
"   </p>",
"   <p>",
"    When the decision is made to add a second agent for mild to moderate ILD,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is often the first choice due to a greater clinical experience with this medication [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/10\">",
"     10",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil is an alternative if the patient has a low level of thiopurine methyltransferase (TPMT) or does not tolerate azathioprine. Some experts use mycophenolate in preference to azathioprine based on the degree of efficacy they have personally observed. The comparative efficacy of azathioprine and mycophenolate mofetil for treatment of",
"    <span class=\"nowrap\">",
"     DM/PM",
"    </span>",
"    associated ILD is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H3#H3\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with impending respiratory failure due to rapidly progressive interstitial pneumonitis, we suggest using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus high dose glucocorticoids with a transition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    plus glucocorticoids after six months. An alternative is to initiate mycophenolate first and transition to cyclophosphamide, if the patient fails to improve.",
"   </p>",
"   <p>",
"    For patients with progression of ILD, but not impending respiratory failure, despite glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , we typically substitute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil for the azathioprine and continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , although formal data to support this choice are lacking.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is an alternate choice after mycophenolate in this situation.",
"   </p>",
"   <p>",
"    Information about the individual agents used to treat interstitial pneumonitis in DM or PM is provided in the sections that follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon data from case series,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is often effective in the treatment of nonspecific interstitial pneumonitis due to DM or PM [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. It is not known if azathioprine is effective in patients with UIP due to DM or PM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=see_link\">",
"     \"Nonspecific interstitial pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link&amp;anchor=H17#H17\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\", section on 'Azathioprine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before beginning",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , patients are usually screened for thiopurine methyltransferase (TPMT) deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H2#H2\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Pharmacology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is usually started at a dose of 25 to 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for the first week to test for drug hypersensitivity. The dose is then increased incrementally by 25 to 50 mg (0.5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    per day every four to six weeks until the desired response is seen or a maximal total dose of 2.5 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (generally not higher than 200",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    even in large individuals) is reached. A lower dose is indicated in patients with renal insufficiency. Additional details about dosing and monitoring are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Dosing and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) is an inhibitor of lymphocyte proliferation that has been used in case reports and case series to treat DM and PM myositis and also nonspecific interstitial pneumonitis (NSIP) associated with DM and PM, scleroderma, and other rheumatic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Clinical trials to assess the efficacy of MMF in ILD due to DM or PM are in progress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Mycophenolate mofetil'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/19/7482?source=see_link&amp;anchor=H387483#H387483\">",
"     \"Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MMF is usually initiated at a dose of 250 mg given twice a day. The target dose is typically 1.5 to 2",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    lower in patients with renal insufficiency. Doses up to 3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    have been reported, but are not recommended by the manufacturer. Information about the dosing and potential side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=see_link\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    have been used in patients with inflammatory myopathy complicated by ILD, including a small number of cases refractory to other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/17-22\">",
"     17-22",
"    </a>",
"    ]. In one series, 13 patients with the antisynthetase syndrome (12 with antibodies to Jo-1) and ILD were treated with tacrolimus for a mean duration of 51 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/17\">",
"     17",
"    </a>",
"    ]. The following benefits were noted: a reduction in the mean",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose by 67 percent and substantial improvements in forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and the diffusing capacity for carbon monoxide (DLCO).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is generally preferred over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for the treatment of",
"    <span class=\"nowrap\">",
"     DM/PM",
"    </span>",
"    associated ILD. General guidelines for the use of tacrolimus and cyclosporine are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Calcineurin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of daily oral or monthly intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has been described in a few case reports and small series of patients with ILD and PM or DM [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. One series evaluated monthly intravenous cyclophosphamide (300 to 800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every four weeks) plus daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for progressive ILD in 17 patients with DM or PM [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/23\">",
"     23",
"    </a>",
"    ]. All patients received at least six courses. Eleven of the 17 patients showed improvement in dyspnea. Six of the seven patients who required supplemental oxygen were able to discontinue its use. Twelve patients had improvements in forced vital capacity (FVC) of at least 10 percent. For the group overall, the mean FVC improved by 15 percent over baseline, from 68 to 83 percent predicted.",
"   </p>",
"   <p>",
"    Information about dosing, monitoring, and preventing side effects during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is typically administered for six months and then transitioned to an alternate immunosuppressive agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ), because of the risk of bladder cancer with longer courses of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H15#H15\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Bladder toxicity with CYC'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is used commonly as a glucocorticoid-sparing agent in DM and PM, it should be used with caution in patients with ILD because of its potential to cause pneumonitis and because drug-induced pneumonitis may be difficult to distinguish from progression of the underlying ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link&amp;anchor=H13#H13\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\", section on 'Drug-induced pneumonitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TRIPLE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with progressive ILD despite the combination of glucocorticoids and one of the second agents listed above, a third immunosuppressive agent may be added. As an example, glucocorticoids, monthly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and a calcineurin inhibitor may be used in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/21,25\">",
"     21,25",
"    </a>",
"    ]. Based on the limited data in support of this approach, an alternate choice would be one of the salvage therapy options described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SALVAGE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some",
"    <span class=\"nowrap\">",
"     DM/PM",
"    </span>",
"    patients with ILD suffer progressive pulmonary dysfunction despite the above therapies. In this setting, superimposed infection, drug-induced pneumonitis, and respiratory muscle weakness must be excluded. The evaluation and treatment of pulmonary infection, drug-induced pneumonitis, and respiratory muscle weakness in patients with DM or PM are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link&amp;anchor=H11#H11\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After exclusion of alternative disease processes, options for salvage therapy include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , intravenous immune globulin (IVIG), and lung transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients with progressive ILD in patients with PM or DM [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Clinical trials using rituximab in DM or PM, including patients with ILD, are ongoing and thus no formal recommendation can be offered at this time. However, if lung biopsy specimens are available and show a preponderance of lymphoid cells that are B cell predominant, then B cell directed therapy could be beneficial. The dosing of rituximab has not been standardized, although a common regimen is to administer two 1 g doses one week apart. The use of rituximab to treat myositis in DM and PM is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link&amp;anchor=H28#H28\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few studies have suggested that IVIG is effective for the myopathy associated with DM or PM [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/30\">",
"     30",
"    </a>",
"    ]. These limited observations provide the rationale for its application as a salvage therapy in patients with refractory ILD, although evidence of efficacy is lacking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Intravenous immune globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For appropriate candidates (eg, under age 60 and without comorbid illness) with severe or progressive lung disease, referral to a transplant center may be appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3480?source=see_link\">",
"     \"Lung transplantation: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ILD due to DM or PM need ongoing monitoring to adjust therapy, according to the disease activity, and to monitor for complications of the disease or its therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Assessing the response and tapering therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to initial therapy should be assessed at four to eight week intervals, or more often if the patient develops worsening symptoms. A favorable response includes a reduction in dyspnea and cough, radiographic clearing, and physiologic improvement, as assessed by forced vital capacity, total lung capacity, diffusion capacity for carbon monoxide, and both resting and exercise oxygen saturation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link&amp;anchor=H8#H8\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\", section on 'Pulmonary function tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One month after initiation of therapy, the initial dose of glucocorticoids is tapered to 0.5 to 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, if the patient has had a favorable response. In patients whose ILD continues to improve or stabilizes with treatment, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose is gradually tapered, aiming to reach 5 to 10 mg daily or on alternate days over the course of 6 to 12 months. Cessation of glucocorticoid therapy may be considered after a year of therapy, if the ILD remains stable.",
"   </p>",
"   <p>",
"    Other immunosuppressive agents are continued for at least one to two years. If the ILD remains in remission or stable, the immunosuppressive agent may be discontinued. However, many patients require long-term immunosuppressive therapy. For these patients, the goal is to maintain control of disease, using a regimen with the least toxicity possible. Flares of DM and PM may occur at any time, although often in the context of tapering immunosuppressive therapy. Whenever dyspnea, cough, and fever develop or worsen, a re-evaluation for possible complications of therapy or alternative explanations for increased dyspnea should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link&amp;anchor=H11#H11\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Spontaneous pneumomediastinum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous pneumomediastinum may develop in a patient with ILD with DM or PM. This usually presents with acute onset of retrosternal chest pain with neck and face swelling due to subcutaneous emphysema. Some patients also complain of dyspnea. This is typically manifest on plain chest radiograph. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link&amp;anchor=H16#H16\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\", section on 'Spontaneous pneumomediastinum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of spontaneous pneumomediastinum usually involves supportive care with rest, observation, and supplemental oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/31\">",
"     31",
"    </a>",
"    ]. Treatment of the underlying ILD is usually initiated or intensified, as described above [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevention of treatment related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant complications of the therapies described above are opportunistic infections and glucocorticoid-related osteoporosis, cataracts, and adrenal suppression; appropriate prophylaxis can help to prevent some of these complications.",
"   </p>",
"   <p>",
"    We suggest Pneumocystis prophylaxis for patients who are on a combination of high-dose glucocorticoid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or more) and another immunosuppressive agent. This suggestion is largely based on data from a retrospective study of 47 patients with DM [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/33\">",
"     33",
"    </a>",
"    ]. More than 25 percent of the patients who did not receive prophylaxis developed infections, primarily P. jirovecii pneumonia. The choice of agents for prophylaxis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of other complications of chronic systemic glucocorticoid therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of ILD in patients with DM or PM is not uniform [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/34\">",
"     34",
"    </a>",
"    ]. The patterns that have been described include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/2,35\">",
"     2,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fulminant disease with fever and rapid progression of radiographic changes and respiratory failure indicative of acute interstitial pneumonitis (AIP).",
"     </li>",
"     <li>",
"      Indolent disease with slow progression both radiographically and clinically over a period of years.",
"     </li>",
"     <li>",
"      Asymptomatic lung disease that is detectable only by chest imaging or pulmonary function tests and does not progress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with inflammatory myositis and symptomatic ILD, mortality is primarily due to progressive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/1,36,37\">",
"     1,36,37",
"    </a>",
"    ]. The prognosis appears to be worse for patients with ILD, than for those without. In one report, for example, patients with ILD had a 40 percent mortality rate after a mean follow-up of 31 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/36\">",
"     36",
"    </a>",
"    ]. This rate was substantially higher compared with a group of historical controls who did not have ILD. Approximately 60 percent of deaths among patients with ILD were due to progressive pulmonary disease. In a separate report, among 107 patients with ILD associated with",
"    <span class=\"nowrap\">",
"     PM/DM,",
"    </span>",
"    33 percent experienced resolution of ILD, 51 percent improvement, and 16 percent worsening; the overall mortality was 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognosis is also affected by the specific type of ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/34\">",
"     34",
"    </a>",
"    ]. As an example, nonspecific interstitial pneumonia (NSIP) appears to have a prognosis similar to that of idiopathic NSIP, with a five-year survival of 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with organizing pneumonia",
"    <span class=\"nowrap\">",
"     (OP)/bronchiolitis",
"    </span>",
"    obliterans organizing pneumonia (BOOP) tend to have the best prognosis and response to treatment, while those with diffuse alveolar damage (DAD) have the worst [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/5\">",
"     5",
"    </a>",
"    ]. The subset of DM known as amyopathic dermatomyositis can present with particularly severe and progressive ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors that predict a poor prognosis include older age, symptomatic ILD, and lower values for vital capacity and diffusing capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/34\">",
"     34",
"    </a>",
"    ]. With respect to radiographic findings, survival is best in patients whose infiltrates have a ground glass appearance, which is most indicative of cellular NSIP, and worst in those with reticular patterns or honeycombing, which are most often due to usual interstitial pneumonia (UIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8313/abstract/6,9,34\">",
"     6,9,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=see_link\">",
"       \"Patient information: Myositis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with dermatomyositis (DM) or polymyositis (PM) who have radiographic interstitial lung disease (ILD) but are asymptomatic and have minimal reductions in lung volumes and diffusing capacity, we suggest a period of observation and serial assessment of clinical status and pulmonary function tests (PFTs). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initiating treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with DM or PM who develop symptomatic ILD, we recommend initiating systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The usual starting dose is oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      ideal body weight per day, to a maximum daily dose of 80 mg. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ILD and DM or PM have a high likelihood of requiring a second agent to control the ILD or enable tapering of glucocorticoids. We suggest adding a second immunosuppressive agent from the outset of therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative is to assess the response to glucocorticoids alone and add a second agent if the ILD is refractory or flares with tapering of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      is the \"second agent\" used most often; patients who do not tolerate azathioprine are usually treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Adding a second agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe and rapidly progressive ILD, defined as significant pulmonary dysfunction and extensive chest radiographic findings at baseline, we suggest adding a second agent to the systemic glucocorticoids, rather than continuing glucocorticoids alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We generally choose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in this setting. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Adding a second agent'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link&amp;anchor=H12#H12\">",
"       \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Cyclophosphamide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have less severe disease, but are not responding to glucocorticoids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , we suggest substituting an alternative immunosuppressive agent for azathioprine and continuing the systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil is our usual choice in this setting;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      is an alternative. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Adding a second agent'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Mycophenolate mofetil'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Calcineurin inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When the ILD is refractory to double agent therapy, triple agent therapy is usually the next step. For disease refractory to triple therapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      or intravenous immunoglobulin may be added. Data in support of these choices are limited. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Triple therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Salvage therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Rituximab'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Intravenous immune globulin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients treated with the combination of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (eg, prednisone 20 mg per day or more) and any other immunosuppressive agent, we suggest prophylaxis against Pneumocystis jirovecii infections (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A reasonable regimen is a single-strength tablet of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/400",
"      </span>",
"      mg) each day. Other regimens for prophylaxis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/1\">",
"      Marie I, Hachulla E, Ch&eacute;rin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/2\">",
"      Dickey BF, Myers AR. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum 1984; 14:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/3\">",
"      Schwarz MI, Matthay RA, Sahn SA, et al. Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature. Medicine (Baltimore) 1976; 55:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/4\">",
"      Fujisawa T, Suda T, Nakamura Y, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005; 32:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/5\">",
"      Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990; 141:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/6\">",
"      Wells AU, du Bois RM. Bronchiolitis in association with connective tissue disorders. Clin Chest Med 1993; 14:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/7\">",
"      Nawata Y, Kurasawa K, Takabayashi K, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol 1999; 26:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/8\">",
"      Salmeron G, Greenberg SD, Lidsky MD. Polymyositis and diffuse interstitial lung disease. A review of the pulmonary histopathologic findings. Arch Intern Med 1981; 141:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/9\">",
"      Bonnefoy O, Ferretti G, Calaque O, et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol 2004; 49:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/10\">",
"      Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/11\">",
"      Takada K, Kishi J, Miyasaka N. Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis: a retrospective study. Mod Rheumatol 2007; 17:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/12\">",
"      Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/13\">",
"      Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009; 337:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/14\">",
"      Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/15\">",
"      Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/16\">",
"      Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease. J Rheumatol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/17\">",
"      Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/18\">",
"      Ochi S, Nanki T, Takada K, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 2005; 23:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/19\">",
"      Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005; 38:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/20\">",
"      Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 2000; 27:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/21\">",
"      Maeda K, Kimura R, Komuta K, Igarashi T. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 1997; 26:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/22\">",
"      Cavagna L, Caporali R, Abd&igrave;-Al&igrave; L, et al. Cyclosporine in Anti-Jo1-positive Patients with Corticosteroid-refractory Interstitial Lung Disease. J Rheumatol 2013; 40:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/23\">",
"      Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/24\">",
"      al-Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol 1989; 16:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/25\">",
"      Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005; 32:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/26\">",
"      Mok CC, To CH, Szeto ML. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand J Rheumatol 2003; 32:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/27\">",
"      Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004; 43:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/28\">",
"      Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005; 32:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/29\">",
"      Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006; 65:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/30\">",
"      Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009; 187:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/31\">",
"      Caceres M, Ali SZ, Braud R, et al. Spontaneous pneumomediastinum: a comparative study and review of the literature. Ann Thorac Surg 2008; 86:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/32\">",
"      Le Goff B, Ch&eacute;rin P, Cantagrel A, et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum 2009; 61:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/33\">",
"      Viguier M, Fou&eacute;r&eacute; S, de la Salmoni&egrave;re P, et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine (Baltimore) 2003; 82:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/34\">",
"      Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011; 63:3439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/35\">",
"      Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008; 63:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/36\">",
"      Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum 1988; 18:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/37\">",
"      Lakhanpal, S, Lie, JT, Conn, DL, Martin II, WJ. Pulmonary disease in polymyositis/dermatomyositis: A clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 1986; 46:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/38\">",
"      Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8313/abstract/39\">",
"      Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4357 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8313=[""].join("\n");
var outline_f8_7_8313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIATING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ADDING A SECOND AGENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TRIPLE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SALVAGE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Assessing the response and tapering therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Spontaneous pneumomediastinum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevention of treatment related complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=related_link\">",
"      Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3480?source=related_link\">",
"      Lung transplantation: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=related_link\">",
"      Nonspecific interstitial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=related_link\">",
"      Patient information: Myositis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/19/7482?source=related_link\">",
"      Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2138?source=related_link\">",
"      Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=related_link\">",
"      Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_7_8314="Inherited disorders associated with conjugated hyperbilirubinemia";
var content_f8_7_8314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inherited disorders associated with conjugated hyperbilirubinemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/7/8314/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8314/contributors\">",
"     Jayanta Roy-Chowdhury, MD, MRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8314/contributors\">",
"     Namita Roy-Chowdhury, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/7/8314/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8314/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/7/8314/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/7/8314/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/7/8314/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that cause hyperbilirubinemia can be classified into those that result in a predominantly unconjugated hyperbilirubinemia and those that are associated with an elevation of both conjugated and unconjugated forms of bilirubin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=see_link\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Excretion of conjugated bilirubin is impaired in a number of acquired conditions (such as alcoholic and viral hepatitis, biliary obstruction, cholestasis of pregnancy) and in inherited disorders (such as Dubin-Johnson syndrome, Rotor syndrome, benign recurrent intrahepatic cholestasis). This topic review will discuss the inherited disorders associated with conjugated hyperbilirubinemia. The other conditions are presented separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elimination of conjugated bilirubin in bile is affected in several inherited disorders that work through different mechanisms. In all these situations, the abnormality of biliary excretion of bilirubin is shared with excretory defect of all or some other organic anions. Inherited syndromes of intrahepatic cholestasis commonly result from mutations in the following genes: SERPINAI (alpha 1- antitrypsin), JAG1 (causing Alagille syndrome), ATP8B1 (also known as FIC1), ABCB11 (BSEP), MDR3 (ABCB4), and MRP2 (causing Dubin-Johnson syndrome). The genetic basis of Rotor syndrome has not been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although Dubin-Johnson syndrome and Rotor syndrome have similar phenotypes (mild, fluctuating elevation of both unconjugated and conjugated bilirubin in plasma), in Dubin-Johnson syndrome biliary excretion of organic anions, except bile acids, is impaired, while Rotor syndrome is a disorder of hepatic storage. Other inherited conditions, like progressive familial intrahepatic cholestasis and benign recurrent intrahepatic cholestasis, cause conjugated hyperbilirubinemia as a consequence of reduced bile flow [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DUBIN-JOHNSON SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1954, Dubin and Johnson [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/3\">",
"     3",
"    </a>",
"    ] and Sprinz and Nelson [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/4\">",
"     4",
"    </a>",
"    ] described patients with predominantly conjugated chronic hyperbilirubinemia that was not associated with hemolysis. The disorder occurs in all races and nationalities and both sexes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. It is rare except in Sephardic Jews in whom the incidence is about 1:3000 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dubin-Johnson syndrome is characterized clinically by mild icterus. Otherwise, patients are asymptomatic, although mild constitutional complaints such as vague abdominal pains and weakness can occur. Icterus can be so mild as to be noted only during intercurrent illnesses, pregnancy, or consumption of oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/6\">",
"     6",
"    </a>",
"    ]. Pruritus is not seen in this condition. Physical examination is usually normal except for the icterus, although hepatosplenomegaly is seen occasionally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine clinical laboratory tests, including the complete blood count, serum albumin, cholesterol, alanine and aspartate aminotransferases, alkaline phosphatase, and prothrombin time are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Fasting and postprandial bile acid levels, which are sensitive indices of liver disease, are normal, reflecting the fact that the genetic abnormality does not affect the transport of most bile acids. Serum bilirubin concentrations are usually between 2 and 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    but may decline to normal levels or be as high as 20 to 25",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Approximately 50 percent of the serum bilirubin is conjugated. Of the conjugated bilirubin, a major fraction is bilirubin diglucuronide. In addition, covalently albumin-bound fraction is found in plasma. Bilirubinuria is common.",
"   </p>",
"   <p>",
"    Oral cholecystography, using even a double dose of the contrast material is unsuccessful in visualizing the biliary system. Visualization may, however, be possible four to six hours after intravenous administration of Iodipamide [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Grossly, the liver is black [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/4\">",
"     4",
"    </a>",
"    ]. It is histologically normal except for the presence of a dense pigment (",
"    <a class=\"graphic graphic_picture graphicRef67304 \" href=\"UTD.htm?14/29/14805\">",
"     picture 1",
"    </a>",
"    ). Electron microscopy reveals that the pigment is contained in the lysosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/10\">",
"     10",
"    </a>",
"    ]. Electron spin resonance spectroscopy suggests that the pigment is composed of polymers of epinephrine metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/11\">",
"     11",
"    </a>",
"    ]. Computerized tomography of patients with Dubin-Johnson syndrome shows a significantly higher attenuation as compared to that of normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Organic anion transport defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uptake of organic anions at the sinusoidal surface of hepatocytes is normal in Dubin-Johnson syndrome, as shown by normal initial plasma clearance of intravenously administered bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], bromosulfophthalein (BSP) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/7,14,15\">",
"     7,14,15",
"    </a>",
"    ], dibromosulfophthalein (DBSP) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/15\">",
"     15",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32450?source=see_link\">",
"     indocyanine green",
"    </a>",
"    (ICG) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], and 125I-labeled rose bengal [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/15\">",
"     15",
"    </a>",
"    ]. However, in 90 percent of patients, plasma BSP concentration shows a secondary increase 90 minutes after intravenous administration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/6,7,16\">",
"     6,7,16",
"    </a>",
"    ]. The secondary rise reflects regurgitation of glutathione-conjugated BSP from hepatocytes to the plasma. A similar secondary rise is seen after intravenous injection of unconjugated bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/11,14\">",
"     11,14",
"    </a>",
"    ], but not after injection of substances, such as DBSP, ICG, and 125I-labeled rose bengal, which are not conjugated prior to excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Although the secondary rise is characteristic of Dubin-Johnson syndrome, it is not diagnostic by itself, because it is also seen in hepatobiliary cholestatic disorders. In addition, BSP testing is no longer performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Urinary coproporphyrin excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total urinary coproporphyrin is normal In Dubin-Johnson syndrome, but over 80 percent of it is coproporphyrin I, in contrast to normal subjects in whom 75 percent of urinary coproporphyrin is coproporphyrin III [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clotting factor VII deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced prothrombin activity, resulting from lower levels of clotting factor VII, is found in 60 percent of the patients with Dubin-Johnson syndrome. Factor VII deficiency is most common among Sephardic Jews originating from Iran, Iraq, and the neighboring areas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. However, reduced factor VII levels are also found among patients from other communities. In some families the two disorders segregate independently, indicating that the linkage is not tight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;A metabolic defect in Corriedale sheep resembles that seen in Dubin-Johnson syndrome. Organic anion transport defects and urinary coproporphyrin excretion pattern are similar to patients with Dubin-Johnson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. However, the most widely used model is the TR-rat [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. In these rats, biliary excretion of conjugated bilirubin and other organic anions is impaired. The predominant coproporphyrin in urine is coproporphyrin I [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lysosomal accumulation of black pigments in the liver occurs after feeding a diet enriched with amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/25\">",
"     25",
"    </a>",
"    ]. Breeding studies show an autosomal recessive inheritance pattern and suggest that the abnormality of a single gene is responsible for the disease. The Golden lion tamarin monkey, which manifests conjugated hyperbilirubinemia, is another animal model for Dubin-Johnson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Molecular mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-bile acid organic anions, such as conjugated bilirubin and other glucuronide or glutathione conjugated substances, are transported into the bile canaliculus from the hepatocyte by the multidrug resistance related protein (MRP-2) (also known as the canalicular multispecific organic anion transporter, cMOAT) (",
"    <a class=\"graphic graphic_figure graphicRef50804 \" href=\"UTD.htm?6/37/6739\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/23,31-34\">",
"     23,31-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The transport is ATP-dependent and is achieved against high concentration gradients. The electrochemical gradient created by the negative intracellular potential of &ndash;35 mV also contributes to the transport of bilirubin glucuronides [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/22,28,35\">",
"     22,28,35",
"    </a>",
"    ] into the bile canaliculus. MRP-2 is one of the ATP-binding cassette (ABC) transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/36\">",
"     36",
"    </a>",
"    ]. Direct evidence for its involvement in canalicular transport came from the discovery of a frameshift mutation in the gene encoding it in the TR-rat [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The human MRP-2 gene has been localized to chromosome 10q23-q24 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/38\">",
"     38",
"    </a>",
"    ]. The exon-intron organization has been elucidated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/39,40\">",
"     39,40",
"    </a>",
"    ] and the human cDNA has been isolated based upon homology with rat MRP-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/41\">",
"     41",
"    </a>",
"    ]. Several different mutations (",
"    <a class=\"graphic graphic_figure graphicRef60737 \" href=\"UTD.htm?18/5/18525\">",
"     figure 2",
"    </a>",
"    ) have been identified in this gene in patients with Dubin-Johnson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/39-44\">",
"     39-44",
"    </a>",
"    ]. Mutations in the ATP-binding region, critical for the functioning of the protein, form a significant proportion of the genetic lesions identified to date [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/40,42\">",
"     40,42",
"    </a>",
"    ]. One mutation causes impaired maturation and mislocalization of the protein (mutation \"h\" in the figure) (",
"    <a class=\"graphic graphic_figure graphicRef60737 \" href=\"UTD.htm?18/5/18525\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/45\">",
"     45",
"    </a>",
"    ]. A mutation at an intronic splice donor site was identified in a patient with Dubin-Johnson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/43\">",
"     43",
"    </a>",
"    ]. Autosomal recessive inherence has been confirmed based upon urinary coproporphyrin analysis in families of affected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Dubin-Johnson syndrome can be made by documenting conjugated hyperbilirubinemia (where at least 50 percent of the total bilirubin is the direct fraction) while the rest of the \"liver function profile\" (serum ALT, AST, alkaline phosphatase, albumin, and prothrombin time) are normal, together with the characteristic urinary coproporphyrin excretion. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Urinary coproporphyrin excretion'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Diagnosis and differentiation from Dubin-Johnson syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dubin-Johnson syndrome is a benign condition and no treatment is required. However, it is important to recognize the condition so as not to confuse it with other hepatobiliary disorders associated with conjugated hyperbilirubinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ROTOR SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotor syndrome is a rare disorder, first described in 1948 by Rotor, Manahan, and Florentin. Since then, it has been reported in several nationalities and races.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome is characterized by chronic conjugated and unconjugated hyperbilirubinemia without evidence of hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/48\">",
"     48",
"    </a>",
"    ]. Although Rotor syndrome had been thought previously to be a variant of Dubin-Johnson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/49\">",
"     49",
"    </a>",
"    ], the two conditions are now understood to be different entities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/50\">",
"     50",
"    </a>",
"    ]. In Rotor syndrome there is a defect in hepatic storage of conjugated bilirubin, which leaks into the plasma, resulting in hyperbilirubinemia. Rotor syndrome is also a benign condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum alkaline phosphatase, alanine aminotransferase, aspartate amino transferase and g-glutamyl transpeptidase levels are normal. Plasma clearance of BSP is delayed, but unlike in Dubin Johnson syndrome, biphasic peaks are not seen [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients exhibit prolonged retention of intravenously injected unconjugated bilirubin and ICG [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/52\">",
"     52",
"    </a>",
"    ]. Transport studies for BSP show a 50 percent reduction in transport maximum of this compound in Rotor syndrome, compared to almost no biliary transport in Dubin-Johnson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In contrast to the finding in Dubin-Johnson syndrome, the gall bladder is usually visualized by oral cholecystography [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver histology is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/49\">",
"     49",
"    </a>",
"    ]. The absence of dark melanin-like pigments differentiates this disorder from Dubin-Johnson syndrome. However, liver biopsy is not required for the differentiation, which can be done on the basis of urinary coproporphyrin analysis (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Urinary coproporphyrin excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total urinary coproporphyrin excretion is increased to 250 to 500 percent of normal and coproporphyrin I constitutes approximately 65 percent of urinary porphyrins [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/50,53\">",
"     50,53",
"    </a>",
"    ]. In obligate heterozygotes, the pattern of excretion is intermediate between that of patients with Rotor syndrome and controls. With respect to coproporphyrin excretion, Rotor syndrome is inherited as an autosomal recessive condition and is distinct from Dubin-Johnson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/53\">",
"     53",
"    </a>",
"    ]. However, the molecular basis of the hepatic storage defect in Rotor syndrome has not been elucidated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177556382\">",
"    <span class=\"h2\">",
"     Molecular mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilirubin entering the liver sinusoids is extracted efficiently by hepatocytes that are closest to the points of entry, the portal vein and hepatic artery. As canalicular excretion of conjugated bilirubin is rate limiting in bilirubin excretion, this leads to the possibility of saturation of the excretion process. Bilirubin excretory capacity of the liver is increased by transport of conjugated and unconjugated bilirubin back into the sinusoidal blood through the sinusoidal surface of the hepatocytes. Bilirubin undergoes re-uptake by hepatocytes downstream to the sinusoidal blood flow via organic anion transporter proteins 1B1 and 1B3 (OATP1B1 and OAPT1B3), encoded by SLCO1B1 and SLCO1B3, respectively. This re-uptake process results in recruitment of a greater number of hepatocytes, thereby increasing the bilirubin excretory capacity of the liver. OATP1B1 and OAPT1B3 have functional overlap. Inactivating mutations or deletion of both SLCO1B1 and SLCO1B3",
"    <em>",
"    </em>",
"    disrupts this re-uptake process, resulting in Rotor syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Notably, mutations of OATP1B1 or OATP1B3 alone do not cause jaundice. However, these transporters mediate the uptake of many other compounds, including several drugs. Reduced-activity OATP1B1 resulting from polymorphisms can result in life-threatening drug toxicities, such as statin-associated myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/55\">",
"     55",
"    </a>",
"    ]. Therefore, great caution should be used in treating patients with Rotor syndrome with drugs that undergo transport by these proteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnosis and differentiation from Dubin-Johnson syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dubin-Johnson and Rotor syndrome should be suspected in patients with mild hyperbilirubinemia (with a direct-reacting fraction of approximately 50 percent) in the absence of other abnormalities of standard liver function tests. Normal levels of serum alkaline phosphatase and gamma-glutamyltranspeptidase help to distinguish these conditions from disorders associated with biliary obstruction.",
"   </p>",
"   <p>",
"    The urinary coproporphyrin excretion pattern assists in the diagnosis and in the distinction between these disorders. In Dubin-Johnson syndrome, the total urinary coproporphyrin excretion is normal but 80 percent is coproporphyrin I (in normal subjects 75 percent of urinary porphyrins are coproporphyrin III). In contrast, in patients with Rotor syndrome, total urinary coproporphyrins are increased to 250 to 500 percent of normal with approximately 65 percent being coproporphyrin I.",
"   </p>",
"   <p>",
"    The plasma BSP clearance can also be used to aid in the distinction between these disorders, although it is no longer available for routine clinical use. In Dubin-Johnson syndrome, plasma BSP clearance shows a characteristic biphasic peak. Retention of the dye is nearly normal 45 minutes after injection, but there is a secondary peak at 90 minutes. In Rotor syndrome, there is increased retention at 45 minutes and no secondary peak is seen.",
"   </p>",
"   <p>",
"    Liver biopsy is not necessary for the diagnosis of either condition. However, if a biopsy is performed for other clinical indications, the dense pigmentation of the liver seen in Dubin-Johnson syndrome (",
"    <a class=\"graphic graphic_picture graphicRef67304 \" href=\"UTD.htm?14/29/14805\">",
"     picture 1",
"    </a>",
"    ) distinguishes it from Rotor syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both Dubin-Johnson and Rotor syndromes, serum bilirubin levels may increase during pregnancy, requiring differentiation from cholestasis of pregnancy. The latter is usually associated with pruritus, which is not a feature of Dubin-Johnson or Rotor syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in Dubin-Johnson syndrome, Rotor syndrome does not require treatment. However, the diagnosis is important to avoid confusion with other hepatobiliary diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FAMILIAL HEPATOCELLULAR CHOLESTASIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Progressive familial intrahepatic cholestasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous group of disorders, characterized by defective secretion of bile acids or other components of bile. With the exception of benign recurrent cholestasis (BRIC), these disorders usually present during infancy or childhood, and are associated with growth failure and progressive liver disease. Many patients present with a coagulopathy due to vitamin K malabsorption. Intractable pruritus is a dominant feature in the early stages of PFIC I and II.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Progressive familial intrahepatic cholestasis type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive familial intrahepatic cholestasis type I (PFIC I), also known as Byler disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/57\">",
"     57",
"    </a>",
"    ] and Greenland familial cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/58\">",
"     58",
"    </a>",
"    ], is caused by a mutation in the P-type ATPase gene (ATP8B1), FIC-1, which has been localized to chromosome 18q21 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/59\">",
"     59",
"    </a>",
"    ]. FIC-1 is located in the canalicular membrane and in cholangiocytes and couples the hydrolysis of ATP to the translocation of acidic phospholipids [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/60\">",
"     60",
"    </a>",
"    ]. How the mutation of FIC-1 causes cholestasis and abnormal bile acid transport is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Progressive familial intrahepatic cholestasis type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive familial intrahepatic cholestasis type II (PFIC II) resembles Byler disease clinically but occurs in non-Byler families, mainly in the Middle East and Europe. It is caused by defects in the gene that codes for the sister P-glycoprotein (SPGP) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/61\">",
"     61",
"    </a>",
"    ], also known as bile salt export pump (BSEP) (",
"    <a class=\"graphic graphic_figure graphicRef50804 \" href=\"UTD.htm?6/37/6739\">",
"     figure 1",
"    </a>",
"    ), which is an ATP-dependent transporter of bile acids from the hepatocytes into the bile canaliculus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/2\">",
"     2",
"    </a>",
"    ]. The SPGP gene (ABCB11) has been localized to chromosome 2q24 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/61\">",
"     61",
"    </a>",
"    ]. Over 80 different mutations in SPGP have been described in patients with PFIC-II [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/62\">",
"     62",
"    </a>",
"    ]. Studies in rats suggest that the mechanisms leading to impaired bile acid transport vary depending upon the specific mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PFIC I and PFIC II are both associated with life-threatening cholestasis. Interestingly, despite this, serum gamma-glutamyltranspeptidase levels are normal or nearly so in both these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatocellular carcinoma (HCC), which is rare in young children, has been reported in ten children less than five years of age with PFIC-II. Thus, ABCB11 mutations represent a previously unrecognized risk for HCC in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver transplantation ameliorates all manifestations of PFIC II, specifically hepatic expression of SPGP. However, in four children with PFIC II caused by different ABCB11 mutations, the disease recurred after liver transplantation, probably as a consequence of the development of high titer of antibodies against BSEP [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. As in the case of ATP8B1, some mutations of ABCB11 are associated with a more benign and recurrent course, presenting in adult cases. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Benign recurrent intrahepatic cholestasis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Progressive familial intrahepatic cholestasis type III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive familial intrahepatic cholestasis type III (PFIC III), involves mutations in the ABCB4 gene (also known as multidrug resistance protein-3 P-glycoprotein [MDR3 or PGY 3]) (",
"    <a class=\"graphic graphic_figure graphicRef50804 \" href=\"UTD.htm?6/37/6739\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/68\">",
"     68",
"    </a>",
"    ]. MDR 3 is thought to replenish the phosphatidylcholine in the outer lipid membrane of the bile canaliculus by translocating it from the inner lipid layer. However, bile salt secretion remains normal. In the absence of phosphatidylcholine translocation, bile acids are thought to damage the canalicular membrane, causing progressive destruction of small bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. PFIC III, which is caused by mutations on both alleles, is distinguished from PFIC I, BRIC, and PFIC II by the markedly elevated gamma-glutamyl transpeptidase activity in the serum [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heterozygous mutations in ABCB4 can reduce biliary phospholipid concentration, resulting in increased risk for cholesterol stones, microlithiasis, or sludge, a syndrome known as low phospholipid-associated cholestasis (LPAC). LPAC should be suspected in patients presenting with cholelithiasis before age 40, recurrence after cholecystectomy, and intrahepatic hyperechogenic foci compatible with sludge or microlithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/71\">",
"     71",
"    </a>",
"    ]. Many patients have a family history of cholelithiasis in first-degree relatives or a clinical history of intrahepatic cholestasis of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=see_link\">",
"     \"Intrahepatic cholestasis of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately one-third of adult patients presenting with unexplained cholestasis have mutations in the coding region of at least one ABCB4 allele [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/73\">",
"     73",
"    </a>",
"    ]. ABCB4 mutations also cause acute recurrent biliary pancreatitis, biliary cirrhosis, and fibrosing cholestatic liver disease in adults with or without biliary symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial care for patients with PFIC addresses the nutritional problems and pruritus caused by chronic cholestasis. Fat-soluble vitamin supplementation and monitoring is necessary, as for other forms of chronic cholestasis. Initial therapy for patients with all forms of PFIC is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    , which may improve liver function in some patients, especially those with PFIC III who often have less severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In patients with PFIC III, ursodeoxycholic acid may relieve the pruritus associated with the disorder, but severe pruritus (most often associated with PFIC I and II) is often unresponsive to conventional treatments with ursodeoxycholic acid, antihistamines, or rifampicin. In such cases, surgical procedures to interrupt the enterohepatic circulation of bile acids are often successful. This can be done by diverting part of the bile flow to an external fistula, where it is discarded [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Biochemical improvements are often seen, suggesting that the diversion procedure might slow the progression of liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Other children have been treated by surgical exclusion of the terminal ileum, but compensatory changes in the intestinal absorption of bile acids may limit the long-term efficacy of this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver transplantation is an important option for patients with end-stage liver disease due to PFIC, and for some patients with pruritus that is unresponsive to the measures described above [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/83\">",
"     83",
"    </a>",
"    ]. Liver transplantation is generally curative for patients with PFIC I and II. However, patients with PFIC I may have ongoing disease due to the extrahepatic expression of FIC-I [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transplantation of normal hepatocytes to repopulate the liver and replace the dying cells has been tried in a mouse model of PFIC III, with partial restoration of phospholipid secretion in the bile [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients presenting with cholelithiasis associated with ABCB4 mutations may require endoscopic or surgical removal of gallstones. Replacement of endogenous lithogenic bile acids with hydrophilic bile acids, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    , has been proposed for prevention of cholelithiasis in these patients. Ursodeoxycholic acid (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight daily) has been used successfully in several adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Benign recurrent intrahepatic cholestasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign recurrent intrahepatic cholestasis (BRIC), first described in 1959, is characterized by intermittent cholestatic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/87\">",
"     87",
"    </a>",
"    ]. Age at first presentation ranges from infancy to late adulthood. The number of attacks can range from several episodes per year to one episode in a decade [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/88-91\">",
"     88-91",
"    </a>",
"    ]. During the attacks, the patients present with conjugated hyperbilirubinemia, malaise, anorexia, pruritus, weight loss, and malabsorption. Laboratory tests reveal biochemical evidence of cholestasis without severe hepatocellular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/89,92,93\">",
"     89,92,93",
"    </a>",
"    ]. Such episodes last for weeks to months followed by a complete clinical, biochemical, and histologic normalization. In a given patient, recurrent attacks resemble each other in symptoms, signs, and duration, although the severity and frequency of the episodes appear to decrease with age. BRIC has long been thought to be associated with intrahepatic cholestasis of pregnancy and cholestasis associated with use of oral contraceptives. In one study, 11 members of kindred of whom three members had been affected by BRIC developed intrahepatic cholestasis of pregnancy, cholestasis associated with oral contraceptives, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver histology reveals noninflammatory intrahepatic cholestasis without fibrosis, regardless of the number and severity of attacks. During remission, liver histology returns to normal whether examined by light or electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family studies suggest a recessive inheritance pattern. Surprisingly, this relatively benign disorder was also found to be associated with mutations of ATP8B1 (FIC-I) and ABCB11 (BSEP) genes, which are associated with PFIC-1 and PFIC-II respectively. Mutations in ABCB11 (BSEP gene) have been also associated with BRIC [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/95\">",
"     95",
"    </a>",
"    ]. As an example, a patient with clinical features of BRIC was found to have two different mutations on the two alleles of the ABCB11: A E186G substitution (previously described in a BRIC-2 case) and a V444A substitution (linked to intrahepatic cholestasis of pregnancy). The compound heterozygosity led to the absence of BSEP in bile canaliculi of hepatocytes. Bile salt excretion was reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been proposed that BRIC caused by mutations of ATP8B1 and ABCB11 should be termed BRIC-1 and BRIC-2, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/95\">",
"     95",
"    </a>",
"    ]. There are clinical differences between these two subtypes suggesting that it may be appropriate to subclassify BRIC into at least two distinct disorders (BRIC type 1 and 2). Pancreatitis is a known extrahepatic manifestation in BRIC caused by the ATPB1 mutations but not in BRIC patients with mutations in ABCB11. Similarly, cholelithiasis has been described in patients with the ABCB11 mutation but not in those with the ATP8B1 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific treatment for BRIC. Liver transplantation is generally not considered because of the episodic and non-progressive nature of the disease, although the pruritus can be severe enough for the patient to seek liver transplantation. Short-term nasobiliary drainage has been reported to improve pruritus in a patient with BRIC, presumably by normalizing serum bile salt concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/98\">",
"     98",
"    </a>",
"    ]. Rapid termination of cholestatic episode was reported in a 34-year-old man with BRIC and secondary renal impairment, following extracorporeal albumin dialysis in a molecular absorbent recycling system (MARS) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/99\">",
"     99",
"    </a>",
"    ]. Administration of colestimide, an anion exchange resin that inhibits intestinal bile acid",
"    <em>",
"    </em>",
"    absorption, resulted in rapid remission of the cholestatic episode in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     BILE CANALICULAR AND STRUCTURAL ANOMALIES OF KNOWN GENETIC BASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic basis of two disorders of involving bile canalicular and structural anomalies has been described: Alagille syndrome and abnormalities of Villin gene expression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Alagille syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alagille syndrome is characterized by the paucity of interlobular bile ducts and the following associated features [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/101-104\">",
"     101-104",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic cholestasis (approximately 90 percent)",
"     </li>",
"     <li>",
"      Cardiac anomalies, most commonly peripheral pulmonic stenosis (85 to 91 percent)",
"     </li>",
"     <li>",
"      Butterfly vertebrae (39 to 87 percent)",
"     </li>",
"     <li>",
"      Posterior embryotoxon (prominent Schwalbe line) of the eye (61 to 88 percent)",
"     </li>",
"     <li>",
"      Dysmorphic facies, consisting of broad nasal bridge, triangular facies, and deep set eyes (77 to 95 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other minor abnormalities seen in these patients consist of growth and mental retardation, developmental delay, renal disease, and pancreatic insufficiency. The syndrome is inherited as an autosomal dominant characteristic. The gene responsible for the condition (JAG-1) has been mapped to chromosome 20p12 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/105\">",
"     105",
"    </a>",
"    ]. A majority of patients (approximately 85 percent) present before six months of age with jaundice and failure to thrive, or cardiovascular symptoms. Chronic cholestasis is associated with elevation of serum bilirubin, gamma-glutamyltranspeptidase and alkaline phosphatase levels. As in all cases of intrahepatic cholestasis, lipoprotein X is present in plasma. In addition, lecithin cholesterol acyltransferase activity is reduced in many, but not all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe liver disease is a major cause of morbidity. Increased plasma bile acid levels may cause severe pruritus, necessitating biliary diversion procedures. Liver transplantation may be required in patients with progressive liver synthetic dysfunction, intractable pruritus, osteodystrophy, or massive variceal bleeding.",
"   </p>",
"   <p>",
"    A study of 163 patients has compared the impact of liver involvement on morbidity and mortality in patients with Alagille syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/107\">",
"     107",
"    </a>",
"    ]. The morbidity was significantly higher in patients who presented with neonatal cholestatic jaundice as compared to those who developed cholestatic jaundice later in life. Such patients also experienced worse short-term survival without transplantation.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    has been associated with symptomatic and biochemical improvement in a few cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Larger clinical trials are needed to determine precisely its place in the management of these patients. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    does not appear to be useful, and does not correct the lipid abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/106\">",
"     106",
"    </a>",
"    ]. As described above, some patients will eventually require liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/107,110\">",
"     107,110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Abnormal villin expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;This inherited disease is characterized by a biliary atresia-like presentation with special ultrastructural features. In a review of 50 children who underwent orthotopic liver transplantation for a clinical diagnosis of biliary atresia, three were found to have aberrant ultrastructural findings and a lack of villin expression in the bile canaliculi, as determined by immunohistochemical staining [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/111\">",
"     111",
"    </a>",
"    ]. Each of these patients had clinical features of cholestasis including elevations in serum alkaline phosphatase (356 to 788 IU), gamma-glutamyl transpeptidase (76 to 203",
"    <span class=\"nowrap\">",
"     U/L)",
"    </span>",
"    and bilirubin (16 to 26",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    All patients had cirrhosis at the time of liver transplantation at the age of two to five years. Histologic examination of the liver showed paucity or absence of bile ducts and only a moderate degree of portal fibrosis at the age of three months, which distinguished these cases from classic biliary atresia. Electron microscopy revealed disordered canalicular microvilli, which were often inverted (ie, projected into the cytoplasm, rather than the canalicular lumen).",
"   </p>",
"   <p>",
"    Absence of villin gene expression is thought to be the mechanism causing this disorder. Villin is a protein involved in binding actin and arranging actin fibers in bundles, which are necessary for generating and maintaining anatomically normal microvilli. The human villin gene has been mapped to chromosome 2q35-36 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/112\">",
"     112",
"    </a>",
"    ]. The protein is expressed in the microvilli of brush-border surfaces in the gastrointestinal tract and kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/113\">",
"     113",
"    </a>",
"    ]. Interestingly, patients with abnormal villin gene expression do not exhibit clinical features of malabsorption, pancreatic abnormality, or renal disease.",
"   </p>",
"   <p>",
"    Villin gene knockout mice show an abnormal response to intracellular calcium and develop colonic ulcers when fed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    sulfate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/7/8314/abstract/114\">",
"     114",
"    </a>",
"    ]. However, in contrast to the human cases, no obvious liver phenotype was found. The mechanistic basis of these discrepancies is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91191006\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elimination of conjugated bilirubin in bile is affected in several inherited disorders that work through different mechanisms. In all these situations, the abnormality of biliary excretion of bilirubin is shared with excretory defect of all or some other organic anions, bile salts, or phospholipids. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dubin-Johnson syndrome is characterized clinically by mild icterus. Otherwise, patients are asymptomatic, although mild constitutional complaints such as vague abdominal pains and weakness can occur. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dubin-Johnson syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rotor syndrome is a rare disorder characterized by chronic conjugated and unconjugated hyperbilirubinemia without evidence of hemolysis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Rotor syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Familial hepatocellular cholestasis includes several inherited disorders including progressive familial intrahepatic cholestasis (subclassified into three types) and benign recurrent intrahepatic cholestasis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Familial hepatocellular cholestasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two genetic disorders characterized by bile canalicular and structural anomalies have been well-described: Alagille syndrome and abnormal villin expression. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Bile canalicular and structural anomalies of known genetic basis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115045892\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/1\">",
"      Liu C, Aronow BJ, Jegga AG, et al. Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis. Gastroenterology 2007; 132:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/2\">",
"      Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/3\">",
"      DUBIN IN, JOHNSON FB. Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. Medicine (Baltimore) 1954; 33:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/4\">",
"      SPRINZ H, NELSON RS. Persistent non-hemolytic hyperbilirubinemia associated with lipochrome-like pigment in liver cells: report of four cases. Ann Intern Med 1954; 41:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/5\">",
"      DUBIN IN. Chronic idiopathic jaundice; a review of fifty cases. Am J Med 1958; 24:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/6\">",
"      Cohen L, Lewis C, Arias IM. Pregnancy, oral contraceptives, and chronic familial jaundice with predominantly conjugated hyperbilirubinemia (Dubin-Johnson syndrome). Gastroenterology 1972; 62:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/7\">",
"      Shani M, Seligsohn U, Gilon E, et al. Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases. Q J Med 1970; 39:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/8\">",
"      DITTRICH H, SEIFERT E. [On the behavior of pigment and biligraffin excretion in a patient with Dubin-Johnson syndrome]. Acta Hepatosplenol 1962; 9:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/9\">",
"      Morita M, Kihara T. Intravenous cholecystography and metabolism of meglumine iodipamide (Biligrafin) in Dubin-Johnson syndrome. Radiology 1971; 99:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/10\">",
"      ESSNER E, NOVIKOFF AB. Human hepatocellular pigments and lysosomes. J Ultrastruct Res 1960; 3:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/11\">",
"      Swartz HM, Sarna T, Varma RR. On the natural and excretion of the hepatic pigment in the Dubin-Johnson syndrome. Gastroenterology 1979; 76:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/12\">",
"      Rubinstein ZJ, Seligsohn U, Modan M, Shani M. Hepatic computerized tomography in the Dubin-Johnson syndrome: increased liver density as a diagnostic aid. Comput Radiol 1985; 9:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/13\">",
"      BILLING BH, WILLIAMS R, RICHARDS TG. DEFECTS IN HEPATIC TRANSPORT OF BILIRUBIN IN CONGENITAL HYPERBILIRUBINAEMIA: AN ANALYSIS OF PLASMA BILIRUBIN DISAPPEARANCE CURVES. Clin Sci 1964; 27:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/14\">",
"      SCHOENFIELD LJ, McGILL DB, HUNTON DB, et al. Studies of chronic idiopathic jaundice (Dubin-Johnson syndrome). I. Demonstration of hepatic excretory defect. Gastroenterology 1963; 44:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/15\">",
"      Erlinger S, Dhumeaux D, Desjeux JF, Benhamou JP. Hepatic handling of unconjugated dyes in the Dubin-Johnson syndrome. Gastroenterology 1973; 64:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/16\">",
"      Nakata F, Oyanagi K, Fujiwara M, et al. Dubin-Johnson syndrome in a neonate. Eur J Pediatr 1979; 132:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/17\">",
"      Koskelo P, Toivonen I, Adlercreutz H. Urinary coproporphyrin isomer distribution in the Dubin-Johnson syndrome. Clin Chem 1967; 13:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/18\">",
"      Kondo T, Kuchiba K, Shimizu Y. Coproporphyrin isomers in Dubin-Johnson syndrome. Gastroenterology 1976; 70:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/19\">",
"      Seligsohn U, Shani M, Ramot B, et al. Hereditary deficiency of blood clotting factor VII and Dubin-Johnson syndrome in an Israeli family. Isr J Med Sci 1969; 5:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/20\">",
"      Seligsohn U, Shani M, Ramot B, et al. Dubin-Johnson syndrome in Israel. II. Association with factor-VII deficiency. Q J Med 1970; 39:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/21\">",
"      Levanon M, Rimon S, Shani M, et al. Active and inactive factor VII in Dubin-Johnson syndrome with factor-VII deficiency, hereditary factor-VII deficiency and on coumadin administration. Br J Haematol 1972; 23:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/22\">",
"      Cornelius CE. Organic anion transport in mutant sheep with congenital hyperbilirubinemia. Arch Environ Health 1969; 19:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/23\">",
"      Alpert S, Mosher M, Shanske A, Arias IM. Multiplicity of hepatic excretory mechanisms for organic anions. J Gen Physiol 1969; 53:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/24\">",
"      Arias IM, Bernstein L, Roffler R, et al. Black liver diseases in Corriedale sheep: Metabolism of tritiated epinephrine and incorporation of isotope into the hepatic pigment in vivo. J Clin Invest 1965; 44:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/25\">",
"      Kitamura T, Alroy J, Gatmaitan Z, et al. Defective biliary excretion of epinephrine metabolites in mutant (TR-) rats: relation to the pathogenesis of black liver in the Dubin-Johnson syndrome and Corriedale sheep with an analogous excretory defect. Hepatology 1992; 15:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/26\">",
"      Jansen PL, van Klinken JW, van Gelder M, et al. Preserved organic anion transport in mutant TR- rats with a hepatobiliary secretion defect. Am J Physiol 1993; 265:G445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/27\">",
"      Kitamura T, Jansen P, Hardenbrook C, et al. Defective ATP-dependent bile canalicular transport of organic anions in mutant (TR-) rats with conjugated hyperbilirubinemia. Proc Natl Acad Sci U S A 1990; 87:3557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/28\">",
"      Jansen PL, Peters WH, Lamers WH. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 1985; 5:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/29\">",
"      Oude Elferink RP, Meijer DK, Kuipers F, et al. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim Biophys Acta 1995; 1241:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/30\">",
"      Schulman FY, Montali RJ, Bush M, et al. Dubin-Johnson-like syndrome in golden lion tamarins (Leontopithecus rosalia rosalia). Vet Pathol 1993; 30:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/31\">",
"      Nishida T, Hardenbrook C, Gatmaitan Z, Arias IM. ATP-dependent organic anion transport system in normal and TR- rat liver canalicular membranes. Am J Physiol 1992; 262:G629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/32\">",
"      Ishikawa T, M&uuml;ller M, Kl&uuml;nemann C, et al. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J Biol Chem 1990; 265:19279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/33\">",
"      Kobayashi K, Sogame Y, Hara H, Hayashi K. Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. J Biol Chem 1990; 265:7737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/34\">",
"      Jedlitschky G, Leier I, Buchholz U, et al. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 1994; 54:4833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/35\">",
"      Nishida T, Gatmaitan Z, Roy-Chowdhry J, Arias IM. Two distinct mechanisms for bilirubin glucuronide transport by rat bile canalicular membrane vesicles. Demonstration of defective ATP-dependent transport in rats (TR-) with inherited conjugated hyperbilirubinemia. J Clin Invest 1992; 90:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/36\">",
"      Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992; 8:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/37\">",
"      Paulusma CC, Bosma PJ, Zaman GJ, et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996; 271:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/38\">",
"      Allikmets R, Gerrard B, Hutchinson A, Dean M. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Genet 1996; 5:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/39\">",
"      Tsujii H, K&ouml;nig J, Rost D, et al. Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology 1999; 117:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/40\">",
"      Toh S, Wada M, Uchiumi T, et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999; 64:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/41\">",
"      Paulusma CC, Kool M, Bosma PJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997; 25:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/42\">",
"      Wada M, Toh S, Taniguchi K, et al. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 1998; 7:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/43\">",
"      Kajihara S, Hisatomi A, Mizuta T, et al. A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome. Biochem Biophys Res Commun 1998; 253:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/44\">",
"      Mor-Cohen R, Zivelin A, Rosenberg N, et al. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J Biol Chem 2001; 276:36923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/45\">",
"      Keitel V, Kartenbeck J, Nies AT, et al. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 2000; 32:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/46\">",
"      Kaplowitz N, Javitt N, Kappas A. Coproporphyrin I and 3 excretion in bile and urine. J Clin Invest 1972; 51:2895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/47\">",
"      Wolkoff AW, Cohen LE, Arias IM. Inheritance of the Dubin-Johnson syndrome. N Engl J Med 1973; 288:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/48\">",
"      Rotor AB, Manahan L, Florentin A. Familial nonhemolytic jaundice with direct van den Bergh reaction. Acta Med Phil 1948; 5:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/49\">",
"      Pereira-Lima JE, Utz E, Rosenberg I. Hereditary nonhemolytic conjugated hyperbilirubinemia without abnormal liver cell pigmentation: A family study. Am J Med 1966; 40:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/50\">",
"      Wolkoff AW, Wolpert E, Pascasio FN, Arias IM. Rotor's syndrome. A distinct inheritable pathophysiologic entity. Am J Med 1976; 60:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/51\">",
"      Wolpert E, Pascasio FM, Wolkoff AW, Arias IM. Abnormal sulfobromophthalein metabolism in Rotor's syndrome and obligate heterozygotes. N Engl J Med 1977; 296:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/52\">",
"      Kawasaki H, Kimura N, Irisa T, Hirayama C. Dye clearance studies in Rotor's syndrome. Am J Gastroenterol 1979; 71:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/53\">",
"      Shimizu Y, Naruto H, Ida S, Kohakura M. Urinary coproporphyrin isomers in Rotor's syndrome: a study in eight families. Hepatology 1981; 1:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/54\">",
"      van de Steeg E, Str&aacute;neck&yacute; V, Hartmannov&aacute; H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 2012; 122:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/55\">",
"      SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008; 359:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/56\">",
"      Kenyon AP, Girling JC. Liver disease in pregnancy. Women's Health Medicine 2005; 2:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/57\">",
"      Clayton RJ, Iber FL, Ruebner BH, McKusick VA. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child 1969; 117:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/58\">",
"      Klomp LW, Bull LN, Knisely AS, et al. A missense mutation in FIC1 is associated with greenland familial cholestasis. Hepatology 2000; 32:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/59\">",
"      Bull LN, van Eijk MJ, Pawlikowska L, et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998; 18:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/60\">",
"      Eppens EF, van Mil SW, de Vree JM, et al. FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte. J Hepatol 2001; 35:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/61\">",
"      Strautnieks SS, Kagalwalla AF, Tanner MS, et al. Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24. Am J Hum Genet 1997; 61:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/62\">",
"      Strautnieks SS, Byrne JA, Pawlikowska L, et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology 2008; 134:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/63\">",
"      Wang L, Soroka CJ, Boyer JL. The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II. J Clin Invest 2002; 110:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/64\">",
"      Jansen PL, M&uuml;ller MM. Progressive familial intrahepatic cholestasis types 1, 2, and 3. Gut 1998; 42:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/65\">",
"      Knisely AS, Strautnieks SS, Meier Y, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006; 44:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/66\">",
"      Jara P, Hierro L, Mart&iacute;nez-Fern&aacute;ndez P, et al. Recurrence of bile salt export pump deficiency after liver transplantation. N Engl J Med 2009; 361:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/67\">",
"      Keitel V, Burdelski M, Vojnisek Z, et al. De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis. Hepatology 2009; 50:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/68\">",
"      Jacquemin E, De Vree JM, Cresteil D, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/69\">",
"      Nies AT, Gatmaitan Z, Arias IM. ATP-dependent phosphatidylcholine translocation in rat liver canalicular plasma membrane vesicles. J Lipid Res 1996; 37:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/70\">",
"      de Vree JM, Jacquemin E, Sturm E, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A 1998; 95:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/71\">",
"      Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001; 120:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/72\">",
"      Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis 2007; 2:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/73\">",
"      Ziol M, Barbu V, Rosmorduc O, et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 2008; 135:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/74\">",
"      Fein F, Hermelin B, Becker MC, et al. Acute recurrent biliary pancreatitis associated with the ABCB4 gene mutation. Gastroenterol Clin Biol 2007; 31:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/75\">",
"      Jacquemin E, Hermans D, Myara A, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997; 25:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/76\">",
"      Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 2009; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/77\">",
"      Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 1988; 95:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/78\">",
"      Arnell H, Bergdahl S, Papadogiannakis N, et al. Preoperative observations and short-term outcome after partial external biliary diversion in 13 patients with progressive familial intrahepatic cholestasis. J Pediatr Surg 2008; 43:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/79\">",
"      Kurbegov AC, Setchell KD, Haas JE, et al. Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile. Gastroenterology 2003; 125:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/80\">",
"      Schukfeh N, Metzelder ML, Petersen C, et al. Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis. J Pediatr Surg 2012; 47:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/81\">",
"      Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, et al. Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg 1998; 33:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/82\">",
"      Kalici��ski PJ, Ismail H, Jankowska I, et al. Surgical treatment of progressive familial intrahepatic cholestasis: comparison of partial external biliary diversion and ileal bypass. Eur J Pediatr Surg 2003; 13:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/83\">",
"      Englert C, Grabhorn E, Richter A, et al. Liver transplantation in children with progressive familial intrahepatic cholestasis. Transplantation 2007; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/84\">",
"      Lykavieris P, van Mil S, Cresteil D, et al. Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation. J Hepatol 2003; 39:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/85\">",
"      de Vree JM, Ottenhoff R, Smith AJ, et al. Long term effects of hepatocyte transplantation in an animal model of progressive familial intrahepatic cholestasis (abstract). Hepatology 1999; 30(4 pt.2):409A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/86\">",
"      De Vree JM, Ottenhoff R, Bosma PJ, et al. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 2000; 119:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/87\">",
"      SUMMERSKILL WH, WALSHE JM. Benign recurrent intrahepatic \"obstructive\" jaundice. Lancet 1959; 2:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/88\">",
"      de Pagter AG, van Berge Henegouwen GP, ten Bokkel Huinink JA, Brandt KH. Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives? Gastroenterology 1976; 71:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/89\">",
"      Tygstrup N, Jensen B. Intermittent intrahepatic cholestasis of unknown etiology in five young males from the Faroe Islands. Acta Med Scand 1969; 185:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/90\">",
"      Tygstrup N, Steig BA, Juijn JA, et al. Recurrent familial intrahepatic cholestasis in the Faeroe Islands. Phenotypic heterogeneity but genetic homogeneity. Hepatology 1999; 29:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/91\">",
"      Klomp LW, Vargas JC, van Mil SW, et al. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology 2004; 40:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/92\">",
"      SUMMERSKILL WH. THE SYNDROME OF BENIGN RECURRENT CHOLESTASIS. Am J Med 1965; 38:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/93\">",
"      Summerfield JA, Scott J, Berman M, et al. Benign recurrent intrahepatic cholestasis: studies of bilirubin kinetics, bile acids, and cholangiography. Gut 1980; 21:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/94\">",
"      Biempica L, Gutstein S, Arias IM. Morphological and biochemical studies of benign recurrent cholestasis. Gastroenterology 1967; 52:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/95\">",
"      van Mil SW, van der Woerd WL, van der Brugge G, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 2004; 127:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/96\">",
"      Kubitz R, Keitel V, Scheuring S, et al. Benign recurrent intrahepatic cholestasis associated with mutations of the bile salt export pump. J Clin Gastroenterol 2006; 40:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/97\">",
"      van der Woerd WL, van Mil SW, Stapelbroek JM, et al. Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Pract Res Clin Gastroenterol 2010; 24:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/98\">",
"      Stapelbroek JM, van Erpecum KJ, Klomp LW, et al. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 2006; 43:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/99\">",
"      Saich R, Collins P, Ala A, et al. Benign recurrent intrahepatic cholestasis with secondary renal impairment treated with extracorporeal albumin dialysis. Eur J Gastroenterol Hepatol 2005; 17:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/100\">",
"      Uegaki S, Tanaka A, Mori Y, et al. Successful treatment with colestimide for a bout of cholestasis in a Japanese patient with benign recurrent intrahepatic cholestasis caused by ATP8B1 mutation. Intern Med 2008; 47:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/101\">",
"      Alagille D, Estrada A, Hadchouel M, et al. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr 1987; 110:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/102\">",
"      Alagille D. Alagille syndrome today. Clin Invest Med 1996; 19:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/103\">",
"      Emerick KM, Rand EB, Goldmuntz E, et al. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 1999; 29:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/104\">",
"      Subramaniam P, Knisely A, Portmann B, et al. Diagnosis of Alagille syndrome-25 years of experience at King's College Hospital. J Pediatr Gastroenterol Nutr 2011; 52:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/105\">",
"      Oda T, Elkahloun AG, Meltzer PS, Chandrasekharappa SC. Identification and cloning of the human homolog (JAG1) of the rat Jagged1 gene from the Alagille syndrome critical region at 20p12. Genomics 1997; 43:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/106\">",
"      Gottrand F, Clavey V, Fruchart JC, Farriaux JP. Lipoprotein pattern and plasma lecithin cholesterol acyl transferase activity in children with Alagille syndrome. Atherosclerosis 1995; 115:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/107\">",
"      Lykavieris P, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut 2001; 49:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/108\">",
"      Clerici C, Gentili G, Dozzini G, et al. [Chronic therapy with ursodeoxycholic acid in a child with Alagille syndrome]. Pediatr Med Chir 1993; 15:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/109\">",
"      Hofbauer LC, Mrozek-Lasota A, Jelinek T, et al. [Endocrinologic and metabolic complications of Alagille syndrome]. Med Klin (Munich) 1997; 92:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/110\">",
"      Hoffenberg EJ, Narkewicz MR, Sondheimer JM, et al. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J Pediatr 1995; 127:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/111\">",
"      Phillips MJ, Azuma T, Meredith SL, et al. Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood. Lancet 2003; 362:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/112\">",
"      Pringault E, Robine S, Louvard D. Structure of the human villin gene. Proc Natl Acad Sci, USA 1991; 88:10811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/113\">",
"      Bretscher A, Weber K. Villin is a major protein of the microvillus cytoskeleton which binds both G and F actin in a calcium-dependent manner. Cell 1980; 20:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/7/8314/abstract/114\">",
"      Ferrary E, Cohen-Tannoudji M, Pehau-Arnaudet G, et al. In vivo, villin is required for Ca(2+)-dependent F-actin disruption in intestinal brush borders. J Cell Biol 1999; 146:819.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3584 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8314=[""].join("\n");
var outline_f8_7_8314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H91191006\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DUBIN-JOHNSON SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Organic anion transport defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Urinary coproporphyrin excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clotting factor VII deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Animal models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Molecular mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ROTOR SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Urinary coproporphyrin excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177556382\">",
"      Molecular mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnosis and differentiation from Dubin-Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FAMILIAL HEPATOCELLULAR CHOLESTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Progressive familial intrahepatic cholestasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Progressive familial intrahepatic cholestasis type I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Progressive familial intrahepatic cholestasis type II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Progressive familial intrahepatic cholestasis type III",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Benign recurrent intrahepatic cholestasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      BILE CANALICULAR AND STRUCTURAL ANOMALIES OF KNOWN GENETIC BASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Alagille syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Abnormal villin expression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91191006\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115045892\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3584\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3584|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/37/6739\" title=\"figure 1\">",
"      Biliary transport proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/5/18525\" title=\"figure 2\">",
"      MRP 2 gene mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3584|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/29/14805\" title=\"picture 1\">",
"      Dubin Johnson Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=related_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=related_link\">",
"      Intrahepatic cholestasis of pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_7_8315="Lung preservation storage";
var content_f8_7_8315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Donor lung preservation during storage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       <strong>",
"        Ventilation",
"       </strong>",
"      </td>",
"      <td>",
"       <p>",
"        Inflate lung(s) to 50 percent total lung capacity or 20 cm H2O of airway peak pressure; then clamp trachea",
"       </p>",
"       <p>",
"        Use an FIO2 of 30 to 50 percent",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Preservation solution",
"       </strong>",
"      </td>",
"      <td>",
"       Low potassium dextran (Perfadex&reg;)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Temperature",
"       </strong>",
"      </td>",
"      <td>",
"       4 to 8&deg;C",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Topical bath solution",
"       </strong>",
"      </td>",
"      <td>",
"       Low potassium dextran (Perfadex&reg;)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Ischemic time",
"       </strong>",
"      </td>",
"      <td>",
"       Less than 8 hours preferred, possibly up to 12",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8315=[""].join("\n");
var outline_f8_7_8315=null;
var title_f8_7_8316="ACC AHA Rx HF normal LVEF";
var content_f8_7_8316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/ESC guideline summary: Management of patients with heart failure (HF) and preserved systolic function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approaches are effective in the management of HF and preserved left ventricular systolic function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Control of hypertension, both systolic and diastolic, according to current guidelines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Control of ventricular rate in atrial fibrillation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Control of pulmonary congestion and peripheral edema with diuretics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approach in the management of HF and preserved left ventricular systolic function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Coronary revascularization for symptomatic or asymptomatic myocardial ischemia that is thought to have an adverse effect of cardiac function.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of the following approaches in the management of HF and preserved left ventricular systolic function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Restoration of sinus rhythm to improve diagnosis in patients with atrial fibrillation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Among patients controlled hypertension, use of beta blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and calcium channel blockers in an attempt to reduce symptoms of HF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Digitalis to reduce symptoms of HF.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8316=[""].join("\n");
var outline_f8_7_8316=null;
var title_f8_7_8317="Causes of constipation";
var content_f8_7_8317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70425%7EGAST%2F62307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70425%7EGAST%2F62307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of chronic constipation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Neurogenic disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Peripheral",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Diabetes mellitus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Autonomic neuropathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Hirschsprung disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Chagas disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Intestinal pseudoobstruction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Central",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Multiple sclerosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Spinal cord injury",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Parkinson disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Irritable bowel syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Drugs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          See separate table",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Non-neurogenic disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypothyroidism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypokalemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anorexia nervosa",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pregnancy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Panhypopituitarism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Systemic sclerosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Myotonic dystrophy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Idiopathic constipation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Normal colonic transit",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Slow transit constipation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dyssynergic defecation",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs associated with constipation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Analgesics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anticholinergics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihistamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antispasmodics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antipsychotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cation-containing agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron supplements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aluminum (antacids, sucralfate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurally active agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opiates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihypertensives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ganglionic blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vinca alkaloids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5HT3 antagonists",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8317=[""].join("\n");
var outline_f8_7_8317=null;
var title_f8_7_8318="Ethylene glycol metabolism";
var content_f8_7_8318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ethylene glycol metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 620px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Blocked by ethanol and fomepizole.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8318=[""].join("\n");
var outline_f8_7_8318=null;
var title_f8_7_8319="Acromioclavicular injury Type I";
var content_f8_7_8319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acromioclavicular injury Type I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Type I acromioclavicular (AC) injuries represent a sprain of the AC ligaments, while the coracoclavicular ligaments remain intact. Often no abnormality is seen on x-ray, but a&nbsp;slight widening of the AC joint may be apparent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_7_8319=[""].join("\n");
var outline_f8_7_8319=null;
